{
  "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
  "created_date": "unknown_year",
  "country": "DK",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "lin lin -Dr. Dr. sotorasib",
      "start_page": 1,
      "end_page": 2
    },
    {
      "heading": "Medicinal Medicinal Products",
      "text": "With With Amgen'Sotorasib Sotorasib (Lumykras) comment comment on:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "the the review",
      "text": "grade grade 3+ 100 100 (20.6%) SELECT-1 SELECT-1 (30%) 100. 100.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "survival. survival.",
      "text": "fit fit (see AIC/BIC) distributions distributions (and and Exponentiel) cancer cancer register: •arms. arms. • arm. arm.",
      "start_page": 3,
      "end_page": 4
    },
    {
      "heading": "estimates. estimates.",
      "text": "of of +the the patient'medicine. medicine.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "the the applicant'analysis. analysis.",
      "text": "medical medical council'of of applicants' case, case, Amgen'Medical Medical Board'550, 550,000/Medicine Medicine Council'000 000 DKK/G12C-muted G12C-muted NSCLC- line. line.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "Yours faithfully,",
      "text": "Amgros Amgros I/T T +F F +45 88713008 Medicin@amgros.dk",
      "start_page": 4,
      "end_page": 5
    },
    {
      "heading": "DBS, SNI",
      "text": "120 120 mg/XXXX XXXX (sotorasib) Lumykras Lumykras (sotorasib). ... ... .... ... ... . ... ................... ... ... [...] ... ... .................................................... ..................... ................................... ................................. ....................... . . . .... ..... ... . ... . .. ... .... . ... ... .................. ....",
      "start_page": 5,
      "end_page": 11
    },
    {
      "heading": "Contact information",
      "text": "authorization authorization hol",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "Denmark",
      "text": "Active Active substance(s) Pharmaceutical form (s) assessment assessment (approved approved therapeutic",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "indications",
      "text": "n Nicholas Sroczynski",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "Lead, Lead, Denmark",
      "text": "nsroczyn@Manager Manager jburmest@LUMYKRAS LUMYKRAS Sotorasib",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "Amgen Amgen Denmark",
      "text": "960mg 960mg (120mg 120mg tablets) LUMYKRAS LUMYKRAS (sotorasib) cancer cancer (_MEDTERM4_) with less than",
      "start_page": 12,
      "end_page": 13
    },
    {
      "heading": "Hospital?",
      "text": "Combination therapy and",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "medication",
      "text": "Packaging types, sizes/n",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "units, and concentrations",
      "text": "to to d/107 107 (1) 107 107 (3) (c) TFEU. TFEU.",
      "start_page": 13,
      "end_page": 17
    },
    {
      "heading": "of of tables",
      "text": "prior prior anti-SELect-1. SELect-1. .................................................... . . . ................................... ................... ..................... ... .... .................................................... ... . .................. . ............................................... ...... . . . .... .................... .... . ... . .. ... . ... ................................................................. ... .................................. [...] .... Adjustment Adjustment • Adjustment Adjustment .................................................. ................................................................................89. 89. Goodness-Patients Patients (ATT)",
      "start_page": 18,
      "end_page": 21
    },
    {
      "heading": "of of figures",
      "text": ".................................................... ..................... ................................... .................. . . . ... ... ................... ... .... ... ... . ................... . .................................................... . ... ... . . Mutant Mutant ...................... __MEDTERM0_ __MEDTERM0_ ................ Flatiron Flatiron KRA's Mutant .............................................................",
      "start_page": 21,
      "end_page": 23
    },
    {
      "heading": "4. Summary",
      "text": "customers. customers.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Population",
      "text": "sequence sequence (NGS) currently currently exist).",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Intervention",
      "text": "novel, novel, first-Use Use (CHMP) cancer cancer (_MEDTERM1_) mg mg (mg mg tablets) administered. administered.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Comparator",
      "text": "75 75 mg/weeks. weeks.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Clinical comparison",
      "text": "a a second- of of head-__medterm6___ __medterm6___ . events events (TRAE) (20% vs 30%) AEs AEs (9% vs 14.5%). of of life(8, 9). safety_related safety_related agents",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "Health economic model",
      "text": "question. question.",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "economic economic evaluation",
      "text": "ratio ratio (ICER) a a willingness-ICER ICER were: (i) ratio ratio (HR) treatment treatment discrimination; (ii) of of docetaxel; (iii) to to loss; (iv) factor factor (HR).",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Disease Disease information",
      "text": "4 4 (1) (b) of Regulation (EU) No 575/following following criteria: approximately approximately 10% and and 26% disease disease (16). 1. 1.",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Lung Cancer",
      "text": "Adenocarcinoma Adenocarcinoma Others",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "Molecular Molecular altars",
      "text": "heterogeneity heterogeneity (17, 18), subtype subtype (19).",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "in in NSCLC",
      "text": "in in active/guanosine guanosine tri/diphosphate (GTP/GDP) (30). the the KRA'estimated estimated 80% substitution substitution (_MEDTERM0_ mutation) 12. 12.",
      "start_page": 27,
      "end_page": 28
    },
    {
      "heading": "and and stagnating",
      "text": "imaging imaging (e.g., tomography tomography [CT]/tomgraphy tomgraphy [PET]-CT scan). disease disease (34). trials trials (35). including including (_MED_MED__MED_IREME_MED,",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "Clinical Clinical presentation",
      "text": "challenging challenging (37). dyspnea dyspnea (shortness of breath), atelectasis (partial/complete lung collapse), effusion effusion (and and lungs) (38).",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "KRAS G12C_mutated KRAS G12C_mutated NSCLC",
      "text": "for for 2L+, inhibitor inhibitor (ICI) chemotherapy chemotherapy (24.49).",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "in in Denmark",
      "text": "NSCLCpatients NSCLCpatients (5). otherwise otherwise stated) __MEDTERM0_MENT __MEDTERM0_MENT (Danish registry analysis) treatment treatment (mean) metastases metastases (%) PS1, PS1, PS<Gender Gender (% female) baseline baseline (% IIIB [vs IV]) history history (% yes) X Key: oncology oncology group; status. status. Note: systemic systemic treatment; systemic systemic therapy; systems systems treatment; *for for X_TIL",
      "start_page": 28,
      "end_page": 29
    },
    {
      "heading": "5 5 Epidemiology",
      "text": "Registry Registry (DLCR) 1623 1623 patients(4). non-square non-square __medterm4_] patients (Data on file(5)).",
      "start_page": 29,
      "end_page": 30
    },
    {
      "heading": "this this application",
      "text": "Sotorasib (LUMYKRASTM) Agency Agency (EMA)",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "treatment treatment options",
      "text": "DLCG DLCG (6), clinical experts (2, 3) basket basket (Table 60).",
      "start_page": 30,
      "end_page": 31
    },
    {
      "heading": "comparators comparators (s)",
      "text": "by by DLCG(6) clinical clinical experts(2, 3).",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "comparator comparator (docetaxel)",
      "text": "75 75 mg/weeks. weeks.",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "Subject",
      "text": "Generic name (ATC-code) Docetaxel (L01CD02) 75 75 mg/infusion. infusion.",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "Treatment:",
      "text": "count count < 500 cells/60 60 mg/mg mg /required. required.",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "5.3 Intervention",
      "text": "107 107 (3) (c) C C - 6. 6.",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Subject",
      "text": "Generic name (ATC-code) Sotorasib (L01XX73) 960mg 960mg (120mg 120mg tablets) Oral Oral tablets",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "other other medications",
      "text": "Treatment duration: tests tests (total total bilirubin) Disease Disease / therapy. therapy.",
      "start_page": 33,
      "end_page": 34
    },
    {
      "heading": "relevant relevant studies",
      "text": "review review (SLR) 107 107 (3) (c) A A - comparators. comparators.",
      "start_page": 34,
      "end_page": 35
    },
    {
      "heading": "relevant relevant studies",
      "text": "B B - study study (journal, journal, year) (completion completion date) 08. 08.2018",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "and and safety",
      "text": "of of head-2. 2., months months (7.9, NE) (on on file) of of therapy",
      "start_page": 35,
      "end_page": 36
    },
    {
      "heading": "X X X",
      "text": "K K - MAIC.",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "100 100 study",
      "text": "D D - study. study.",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "100 100 results",
      "text": "__MEDTERM0_ __MEDTERM0_ (CI) months months (5.1- (73) 8.2 months) Median __MEDTERM1_ (ci) months months (73) 10.0-NE months) 9 9 (7.1%) (73)",
      "start_page": 36,
      "end_page": 37
    },
    {
      "heading": "TRAEs - n (%)",
      "text": "TRAEs grade 3+ - n (%) 26 26 (20.6%) (73) 126 126 11(8.7%), (73)",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "AEs-n (%)",
      "text": "AEs grade 3+n (%) 77 77 (61%) (73) EORTC QLQ-C30",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "survival survival (PFS)",
      "text": "8 8 (95% CI 5.1-82) months (Figure 2). 52. 52.2% (95% 6-60. 6-60.9) 16. 16.3% (95% 4-28. 4-28.2) patients patients (56.5%) 13 13 (10.5%) patients patients (33.1%) 25 25 (20.2%) 7 7 (5.6%) 5. 5.1%) disease. disease.",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "survival survival (OS)",
      "text": "5 5 (95% CI 10.0-NE) months (Figure 3). 75. 75.5% (95% 8-82. 8-82.2) 51. 51.4% (95% 9-60. 9-60.1) 59 59 (46.8%) patients patients (53.2%) 56 56 (44.4%) 9 9 (7.1%) included (71).",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "safety safety profile",
      "text": "events events (TREAs) patients patients (69.8%).",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "life life (HRQoL)",
      "text": "health health status/change change (were were > 5 patients) 9 9 (cycle 3) to -5.3 (cycle 11) (see Error! found. found.).",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "EORTC EORTC QLQ-",
      "text": "107 107 (3) (c) Parties. Parties.",
      "start_page": 38,
      "end_page": 39
    },
    {
      "heading": "SELECT-1 SELECT-1 study",
      "text": "2016 2016 (72). D D - study. study.",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "SELECT-1 SELECT-1 results",
      "text": "Results Results (IQR) Placebo Placebo + 8 8 (1.4-5.5) months (72) Bo Bo + 9 9 (3.8-20.1) months (72) AEs AEs (%) Placebo+ 37 37 (14.5%) (72), AEs grade 3+ (%) Placeb + 115 115 (45.0%) (72). NA NA Key: NA, not available; __MIDTERM1__, overall survival; _MEDTERM0_, progression-free survival; outcomes. outcomes.",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "survival survival (PFS)",
      "text": "date date (June 7, 2016), 8 8 (5-4. 5-4.5) months (Figure 4) (72). placebo placebo + docetaxel (treatment treatment comparison) and __medterm0__+ docetaxel. Key: HR, Hazard ratio; survival. survival.",
      "start_page": 39,
      "end_page": 40
    },
    {
      "heading": "survival survival (OS)",
      "text": "date date (June 7, 2016), months months (8-20. 8-20.1) events events (Figure 5). placebo placebo + docetaxel (treatment treatment comparison) docexole. docexole. Key: HR, Hazard ratio; survival. survival.",
      "start_page": 40,
      "end_page": 41
    },
    {
      "heading": "safety safety profile",
      "text": "affected affected 10% diarrhoea diarrhoea (89 events, 35%), fatigue (79 events, 31%), alopecia (64 events, 25%), and nausea (62 events, 24%). anemia anemia (11 events, 4%), fatal (10 events,.4%), neutropenia (10 events; and (7 events, 3%). 76 patients (30%) hospitalization hospitalization (72). events events (45%), pregnancy, pregnancy, 32% docetaxel. docetaxel.",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "life life (HRQoL)",
      "text": "docetaxel. docetaxel.",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "and and safety",
      "text": "sources sources (74).",
      "start_page": 41,
      "end_page": 42
    },
    {
      "heading": "MAIC MAIC overview",
      "text": "study study (75). in in (n = 126) the the Commission'107 107 (3) (c) removal. removal. Variable'process. process.",
      "start_page": 42,
      "end_page": 43
    },
    {
      "heading": "Population Population characteristics",
      "text": "charts charts (SELECT-1) N = 126 N = 256 Age (mean) Gender Gender (% female) 50% 43% Brain metastases (%) 21% NRb ECOG (% PS 0) 70% 59% Race (% white) 82%c 95% % KRAS-G12C 100% 42%d Anti-PD-(L) prior prior line(s) 91% 0% lines lines (% with 1/2/3 prior lines) 43%/35%/22% 100%/0% baseline baseline (% IIIB [vs IV]) 97% 96% Histology (% Non-squamous) 99% 95% Smoking status (% ever smoker) 93% 92% mutations mutations (_MEDTERM2___L_REV1",
      "start_page": 43,
      "end_page": 44
    },
    {
      "heading": "MAIC MAIC approach",
      "text": "shall shall apply: (i) transferable transferable securities; (ii) financial financial instruments; (iii) in in securities; or (iv) foreign foreign currency; (v) foreign foreign currencies; (vi) trading trading purposes; (vii) treatment. treatment.",
      "start_page": 44,
      "end_page": 45
    },
    {
      "heading": "Category Covariate",
      "text": "ECOG ECOG (0, 1) * metastases metastases (Y, N) baseline baseline (Y; N) * expression expression (<5%, >5%) following following mutations/alterations: Age Age * status status (of of smoking) * metastasies metastasies (Y and N) metastasese metastasese (Y), N) metastasis metastasis (or or more) therapies therapies (1, 2, 3) date date (<3 3 - 6 months, > K K - MAIC.",
      "start_page": 45,
      "end_page": 46
    },
    {
      "heading": "MAIC MAIC Results",
      "text": "risks. risks.",
      "start_page": 46,
      "end_page": 47
    },
    {
      "heading": "1 1 OScurve",
      "text": "sotorasib sotorasib (in blue) SELECT-1 SELECT-1 (in yellow) in in Error! found. found., 100 100 (in Blue) SELECT-1 SELECT-1 (yellow) Error Error ! found. found.; results. results.",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "A B",
      "text": "Key: KM, Kaplan-Meier; indirect indirect comparison; survival. survival. A: curve, curve, B: curve. curve. Note: of of weights",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "2 2 PFScurve",
      "text": "sotorasib sotorasib (in blue) SELECT-1 SELECT-1 (in yellow). Error! 100 100 (in Blue) vs: docecent-1 docecent-1 (In yellow). in in Error!",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "and and __MIDTERM1__results",
      "text": "included included (i) important important (SET 1) and (ii) adjustment adjustment (Set 2). MAIC MAIC analyses; in in error! HR_page. HR_page.",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "vs. vs. docetaxel",
      "text": "limits limits (MAIC), sotorasib",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "the the primary",
      "text": "at at DMC(7).",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "comparator comparator docetaxel",
      "text": "at at DMC(7). in in Error! found. found., Error Error ! estimated estimated hazard",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "analysis analysis (X).",
      "text": "results. results.",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "2 2 Safety",
      "text": "grade grade 3+ CodeBre100. CodeBre100.",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "adverse adverse events",
      "text": "months months (range: 0.2-17.8) for sotorasib (73), months months ( range: 0.1-27.4) for docetaxel (72) (4 4 months). soorasib soorasib (8.7%) and docetaxel (14.5%), treatments. treatments. (0.8) 2 2 (1.6) 1 (0.8) 1 (0.5) 1 (2) 2 2 (0.6) 1 (0.8) 1 (0.6).",
      "start_page": 49,
      "end_page": 51
    },
    {
      "heading": "and and docetaxel",
      "text": "_MEDERM2___. _MEDERM2___.",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "8.1 Model",
      "text": "107 107 (1) 3. 3.5% outcomes. outcomes.",
      "start_page": 52,
      "end_page": 53
    },
    {
      "heading": "were were obtained",
      "text": "tariff tariff set(86) and the EQ-clinical clinical practice",
      "start_page": 53,
      "end_page": 54
    },
    {
      "heading": "Patient Patient population",
      "text": "SELECT-1. SELECT-1.",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "Table 19.",
      "text": "documentation documentation / etc. etc. (including source) Age Age (mean) older. older. (2, 3.5) (see Table 1) Gender (% female) 50.0% 50.0%) practices practices (2, 3, 5) (See Table 1) Weight (kg) be be similar(2, 3) area area (m2) be be comparable(2,3)",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "2 2 Sotorasib",
      "text": "Sotorasib (LUMYKRASTM) the the EMA",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "Table 20. Intervention",
      "text": "clinical clinical (including source) (number/practice practice (including sources source) if known) mg mg (mg mg tablets) duration duration / toxicity toxicity treatment: • models. models.",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "3 3 Comparators",
      "text": "75 75 mg/weeks. weeks.",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "Table 21. Comparator",
      "text": "clinical clinical (including source) (number/practice practice (including sources) source) 75 75 mg/duration duration / toxicity toxicity treatment: the the models",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "effectiveness effectiveness outcomes",
      "text": "2. 2., 3. 3.5",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "reaction reaction outcomes",
      "text": "of of ≥ 0.5% arms arms (sotorasib and docetaxel) cut cut (87). the the SELECT-1(72).",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "Table 22.",
      "text": "Sotorasiba Sotorasiba Docetaxelb",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "5. 5.6% 0.0%",
      "text": "Neutropenia 0.8% 1.6% Note: cut-off cut-off (87) to to treatment(72)",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "relative relative effectiveness",
      "text": "direct direct head-data, data, goodness-guidance guidance (TSD 14) (88). anti anti PD-(L)results. results.",
      "start_page": 56,
      "end_page": 57
    },
    {
      "heading": "MAIC MAIC results",
      "text": "included included (i) important important (SET 1) and (ii) adjustment adjustment (Set 2). in in Error! X-unit X-unit X;",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "Overall Overall survival",
      "text": "sotorasib sotorasib (in blue) SELECT-1 SELECT-1 (in yellow) in in Error! 100 100 (in Blue) SELECT-1 SELECT-1 (i Yellow) Error Error ! survival. survival.",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "A B",
      "text": "Key: KM, Kaplan-Meier; indiect indiect comparison; survival. survival. A: adjusted, B: 14 14 (88). fitting fitting (limited limited model) R R (0. 0.3).",
      "start_page": 57,
      "end_page": 58
    },
    {
      "heading": "Statistical goodness-of-fit",
      "text": "Glossary-criterion criterion (AIC), criteria criteria (BIC) models models (Table 23). 107 107 (1) the the goodness-sotorasib. sotorasib.",
      "start_page": 58,
      "end_page": 61
    },
    {
      "heading": "observed observed data",
      "text": "below below (Error! found. found.). well well (Error! notfound. notfound.).",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "X",
      "text": "Key: KM, Kaplan-Meier; indirect indirect comparison; survival. survival.",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "XX",
      "text": "91. 91.3% 91.0% 92.9% 95.8% 94.7% 95.5% 76. 76.0% 75.6% 77.7% 76.9% 78.0% 77.4% 57. 57.8% 57.7% 57.9% 55.7% 56.0% 56.1% 85. 85.8% 85.5% 88.3% 89.1% 89.2% 89.3% 63. 63.3% 62.7% 65.5% 65.7% 62.7% 61.0% 61.6% 40. 40.0% 39.9% 39.9% 38.2% 37.0% 38.1% 38.1% Key: Exp, exponential; GG, Generalized gamma; survival. survival.",
      "start_page": 61,
      "end_page": 62
    },
    {
      "heading": "curve curve selection",
      "text": "the the goodness-data. data.",
      "start_page": 62,
      "end_page": 62
    },
    {
      "heading": "long-term long-term extrapolations",
      "text": "fitting fitting (restricted) in in Error! found. found..",
      "start_page": 62,
      "end_page": 62
    },
    {
      "heading": "X",
      "text": "approximately approximately 5% presented presented (and and Weibull) and and was",
      "start_page": 62,
      "end_page": 62
    },
    {
      "heading": "5-years 5-years (10-years 10-years (rate, rate, duration",
      "text": "107 107 (1) Treaty. Treaty.",
      "start_page": 63,
      "end_page": 63
    },
    {
      "heading": "Progression-free Progression-free survival",
      "text": "Error! sotorasib sotorasib (in blue) SELECT-1 SELECT-1 (in yellow). Error! KM KM .100 100 (in Blue) vs: Select-1 Select-1 (yellow). For the __MIDTERMM0]relative relative survival: same. same.",
      "start_page": 63,
      "end_page": 63
    },
    {
      "heading": "A B",
      "text": "Key: KM, Kaplan-Meier; indirect indirect comparison; survival. survival. A: adjuvanted time-14 14 (88). jointly jointly (restricted restricted models) R R (0. 0.3) distribution distribution (Table 24).",
      "start_page": 63,
      "end_page": 63
    },
    {
      "heading": "Statistical goodness-of-fit",
      "text": "Goodness-produced produced (unrestricted and restricted) models models (Table 24). Schoe Schoe Key: ha ha -residua residua -direct direct comparison; direct direct compare; MAIC MAIC spsion- General General Business",
      "start_page": 64,
      "end_page": 65
    },
    {
      "heading": "base-case base-case MAIC",
      "text": "Key: indirect indirect comparison; extrapolation. extrapolation.",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "observed observed data",
      "text": "below below (Error! found. found.). well well (Errror! notfound. notfound.).",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "X",
      "text": "Key: KM, Kaplan-Meier; indirect indirect comparison; survival. survival.",
      "start_page": 67,
      "end_page": 67
    },
    {
      "heading": "curve curve selection",
      "text": "107 107 (1) Treaty. Treaty.",
      "start_page": 67,
      "end_page": 68
    },
    {
      "heading": "long-term long-term extrapolations",
      "text": "found. found.",
      "start_page": 68,
      "end_page": 68
    },
    {
      "heading": "survival survival outcomes",
      "text": "analyses analyses (no MAIC), HR HR (was was unclear), as as follows: • distribution distribution • model model (best-fitting best-fitting model)",
      "start_page": 68,
      "end_page": 68
    },
    {
      "heading": "1 1 Sotorasib",
      "text": "100 100 (75) discrimination discrimination (TTD) and PFS (progression. progression.",
      "start_page": 68,
      "end_page": 69
    },
    {
      "heading": "of of X) PFScurve. PFScurve.",
      "text": "CodeBreaK CodeBreaK 100: curve curve (Error! found. found.). below. below.",
      "start_page": 69,
      "end_page": 69
    },
    {
      "heading": "X",
      "text": "For For example: • assume assume TTD=model model (than than PFS).",
      "start_page": 69,
      "end_page": 69
    },
    {
      "heading": "2 2 Docetaxel",
      "text": "docetaxel. docetaxel.",
      "start_page": 69,
      "end_page": 70
    },
    {
      "heading": "X",
      "text": "Key: PFS, progression-free survival; interruption. interruption.",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "data data • summarized:",
      "text": "data. data.",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "values values (HSUV)",
      "text": "the the EQ-The The EQ-5-visit visit (~ of of sotorasib).",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "100 100 EQ-5D-5L",
      "text": "tariff tariff (Error! found. found.).",
      "start_page": 70,
      "end_page": 71
    },
    {
      "heading": "X",
      "text": "Key: Danish EQ-5D-5L index (86). Note: reported reported EQ-5-cut. cut.",
      "start_page": 71,
      "end_page": 71
    },
    {
      "heading": "X",
      "text": "Key: Danish EQ-5D-5L index (86) Note: reported reported EQ-5-cut. cut.",
      "start_page": 71,
      "end_page": 71
    },
    {
      "heading": "measures measures analysis",
      "text": "found. found.. scores scores (Error! Ref or! notfound. notfound..",
      "start_page": 71,
      "end_page": 71
    },
    {
      "heading": "the the Denmark",
      "text": "threshold threshold (0.080), visits visits (the the 95% Cis). the the EQ-4. 4.",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "case case (health state utilities)",
      "text": "Danish Danish EQ-5D-5L value set(86) (Error! found. found.), guidelines. guidelines.",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "death death utilities",
      "text": "Danish Danish EQ-set set (86) in in Error! found. found..",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "significant significant (X (Error! found. found.).",
      "text": "analyses. analyses.",
      "start_page": 73,
      "end_page": 73
    },
    {
      "heading": "modality modality disutility",
      "text": "Mean Mean (95% CI)* TA484 TA484 [assumption](90) 047 047 (0. 0.077) Nafees 2008(91) 073 073 (0. 0.110) Naphees 2008(92) 050 050 (0. 0.060) 484 484 [assumption] (82, 90, 91) TA484 TA484 (assumption](90) 0090 0090 (0. 0.120) 050 050 (0. 0.006) 347, 347, 520; 550 550 (0. 0.774) Doyle 2008 (8) Febre neutropenia.",
      "start_page": 73,
      "end_page": 74
    },
    {
      "heading": "resource resource use",
      "text": "dk dk (94). 100 100 (73.95.96).",
      "start_page": 74,
      "end_page": 75
    },
    {
      "heading": "Administration Administration costs",
      "text": "3 3 weeks(92).",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "management management costs",
      "text": "A A summary",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "Hb 31",
      "text": "L+D (DIFFMAS) Liver Liver (ALT) 24 Livers (AST) 24",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "Table 29.",
      "text": "unit unit (DKK) 2021, 2021, 04MA98: years, years, Diagnosis: DC349: lung cancer UNS(98). 2022, 2022, 30PR06: complicated, complicated, Diagnosis: dc349; uns uns Procedure: scanning scanning chest(98) cycle cycle • Progression-free",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "treatment treatment cost",
      "text": "NSCLCpatients NSCLCpatients (2, 6). experimental experimental treatment(2). analysis. analysis.",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "Biomarks Biomarks testing",
      "text": "clinical clinical experts(2, 3). model. model.",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "resource resource use",
      "text": "DID, DID, WW: UNGi-Twww-Tah-Ta-Tay-TAt-T Away-Tab-Tough-Tube-Dut-Tace-Taw-Tuck-Tact-Tawn-Trad-Trand-Oat. Diagnosis: DD7228: 2021, 2021, 06MA11: Bidiag. Bidiag., Diagnosis: 114, 114, Diagnos: DDG 2021, DDKK) 2021, 2021, 16MA98: MDC16 1-Day-daygroup, Pat.",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "transport transport cost",
      "text": "DMC DMC guidelines(99) (see Table 32). g. g., Resource Resource (DKK) Medicinal Medicinal products",
      "start_page": 77,
      "end_page": 78
    },
    {
      "heading": "administration with sotorasib",
      "text": "of of benzoletaxel(92) minutes. minutes. assumet",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "consultation",
      "text": "mins mins . assumet",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "Base-case Base-case overview",
      "text": "assessments. assessments.",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "TTD",
      "text": "Docetaxel: MAIC MAIC Adjusted: •low low effective",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "Importation· (SET 1) samples size.",
      "text": "located. located. Key: 2L, second-line; medications medications council; of of life; IV, intravenous; indirect indirect comparison; NSCLC, non-small-cell lung cancer; _MEDTERM1_, progression-free survival; __MEDTERM2_, overall survival; analysis analysis set; treatment treatment interruption; adverse adverse event",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "Base-case Base-case results",
      "text": "in in Error! found. found.. ratio ratio (ICER) of X NOK/a a willingness-QAly. QAly. XX",
      "start_page": 80,
      "end_page": 80
    },
    {
      "heading": "X X",
      "text": "Key: AE, adverse event; cost-effect cost-effect ratio; LY, life-years; monetary monetary benefit; WTP, willingness-to-pay; years. years.",
      "start_page": 80,
      "end_page": 80
    },
    {
      "heading": "sensitivity sensitivity analyses",
      "text": "in in Error! found. found.. were were (i) discontinuation, discontinuation, (ii) docetaxel, docetaxel, (iii) sotoraseb, sotoraseb, (iv) and and (v) disturbance. disturbance.",
      "start_page": 80,
      "end_page": 80
    },
    {
      "heading": "X",
      "text": "Key: Admin, administration; AE, adverse event; HR, hazard ratio; IV, intravenous; __MEDTERM0_, progression-intensity; TTD, time-to-treatment discontinuation.",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "Scenario Scenario analysis",
      "text": "distribution, distribution, log-__medterm1__. __medterm1__. -ibution. ibution. urvival; receive receive 100% dosage. dosage. Key: AE, adverse event; caused. caused.",
      "start_page": 81,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "sensitivity sensitivity analyses",
      "text": "in in Error!",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "X X X",
      "text": "Key: cost-effectiveness cost-effectiveness ratio; Incr., incremental; year. year. Error! curve curve (Error! Reference",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "found. found.), a a X% the the DKK",
      "text": "threshold. threshold.",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "X",
      "text": "Key: life life year; o-pay. o-pay.",
      "start_page": 84,
      "end_page": 84
    },
    {
      "heading": "X",
      "text": "Key: life life year; WTP, willingness-to-pay.",
      "start_page": 85,
      "end_page": 85
    },
    {
      "heading": "impact impact analysis",
      "text": "model model (BIM) Denmark Denmark . economy. economy.",
      "start_page": 85,
      "end_page": 85
    },
    {
      "heading": "market market uptake",
      "text": "of of 5%, physician. physician.",
      "start_page": 85,
      "end_page": 86
    },
    {
      "heading": "Budget Budget impact",
      "text": "as as default",
      "start_page": 86,
      "end_page": 86
    },
    {
      "heading": "Scenario Scenario analysis",
      "text": "two two scenarios: - year. year. - in in Error! Error Error ! found. found..",
      "start_page": 86,
      "end_page": 86
    },
    {
      "heading": "submitted submitted documentation",
      "text": "injury. injury.",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "Clinical outcomes",
      "text": "measures, measures, PFS",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "monotherapy monotherapy (X]), in in median",
      "text": "PFS(7). monotherapy monotherapy (X), median median __medterm1___(7). docetaxel. docetaxel.",
      "start_page": 88,
      "end_page": 88
    },
    {
      "heading": "Strengths",
      "text": "practice practice (1. 1.5) compatible. compatible.",
      "start_page": 88,
      "end_page": 88
    },
    {
      "heading": "Limitations",
      "text": "the the Commission'107 107 (3) (c) 108 108 (3) 108 108 (1) 108 108 (2) Agreement. Agreement.",
      "start_page": 88,
      "end_page": 88
    },
    {
      "heading": "Health economics",
      "text": "docetaxel docetaxel EUR/4 4 (1) of Regulation (EU) No 575/the the willness-scenario. scenario.",
      "start_page": 88,
      "end_page": 89
    },
    {
      "heading": "Conclusion",
      "text": "NSCLC NSCLC patient'mutation. mutation.",
      "start_page": 89,
      "end_page": 90
    },
    {
      "heading": "12. References",
      "text": "HOUSEHOLD HOUSEHOLD [Available Available from: caregiovers/lung cancer-101/treatment options/targeted-therapy. Last updated: 16 April,. cancer cancer (_MEDTERM2__) in Europe: Res. Res. 2019;28(7):2010 2010 statement: Trials. Trials. 2010;11(1):amount amount (in EUR) Collaboration Collaboration (1) Reviews Reviews & Dissection (CRD; York, UK) Excellence Excellence (NICE), Meta-Analysiss Meta-Analysiss (66), Trials Trials (CONSORT) and statements (66-70).",
      "start_page": 92,
      "end_page": 98
    },
    {
      "heading": "Search Strategies",
      "text": "economy economy operator'principle. principle.",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "Embase • original search",
      "text": "107 107 (1) Reviews Reviews (Cochrone Revi # lung lung cancer/ cancer cancer / 2 lung Cancer/ 5 5 (carcinom$ 6 6 lung$.2 2 .",
      "start_page": 99,
      "end_page": 102
    },
    {
      "heading": "Embase - 2021 update",
      "text": "($$$*[t] $$$#$$%$$=$$£$$€$$ #$$ $$ $ $$##$ $#$# $$*$$&$$_$$\"$$~$$x$$+$$^$${$$1$$2$$3$$5$$0$$6$$4 or $$4 and $6$5 $$7$$9$$and and 6) crossover procedure/ or double-blind procedure/single-blind single-blind proceeding/ (random$ or or factorial$ or crossover$ or Crossover $ or cross-over$, adj adj blind$) or (singl$ adj blank$ or assigg$ or allocat$ 11 11 (animal$ not human$).14 14 (2020 Sep* or 2020 Oct* or 20 Nov* or 2020. Dec* to to ed=mized mized ver$ $ o nteer$ Jan*). Treaty Treaty (81 81 EC) EC EC (81 81 (1) EC) Treaty. Treaty.",
      "start_page": 102,
      "end_page": 106
    },
    {
      "heading": "• Reference lists",
      "text": "relevant relevant SLRs/scanned. scanned.",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "Single-arm Single-arm Trials",
      "text": "Justice Justice (as as \"First First Instance'), Auditors Auditors (hereinafter \"the General Court'), Bank Bank (\"the Court') Authority Authority (\"the Administrative Court'), Regulation Regulation (EU) No 1071/Union Union (\"the EEA Agreement'), thereof. thereof.",
      "start_page": 106,
      "end_page": 107
    },
    {
      "heading": "to to yr=\"2014 -Current' 71 463",
      "text": "colon colon cancer/ rectum rectum cancer/or colorectal tumor/ 6 6 ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or segmo$ or rectosigm$ or bowl$ or or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or metastas$ or meta-sta$ or sarcoma$or adenom$or lesion$)).ti,ab.",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "ras ras oncogene/ 9909",
      "text": "13 13 epidemiology/14 14 incidence/or accident.ti;15 15 prevalence/overall overall survival/or (su su long$ survival* or survival anal$).free free survival/ or (procession 18 (rate rate ORR_).mp. 19 (21 21 or/Case Case study/pay. pay.",
      "start_page": 108,
      "end_page": 109
    },
    {
      "heading": "to to yr=\"2014 -Current' 29 081",
      "text": "colon colon cancer/ rectum rectum cancer/or colorectal tumor/6 6 ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or segmo$ or rectosigm$ or bowl$ or or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or metastas$ or meta-sta$ or sarcoma$or adenom$or lesion$)).ti,ab.",
      "start_page": 109,
      "end_page": 109
    },
    {
      "heading": "ras ras oncogene/ 12 293",
      "text": "((or or k-ki-ras or c-Kirsten Kirsten RAS) adj5 (mutation$ or mutant$ or or gene$ or translocation$ or oncogene$ or fusion$ or expression$ or over?expression$ or amplification$ or inversion$ or deletion$)).13 13 epidemiology/14 14 incidence/15 15 prevalence/to to yr=\"2014 -Current.$ (in in DARE; records were established] colon colon cancer/ or ectosigm$ or or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignant$ or tumo$ or or adenocarcinoma$ or meta$ or meta-sta$ or sarcoma$ or adenom$or lesion$) to to ry=\"2009 -Curiant\" [in in DARE; or or absented] ras ras oncogene/ 11 ((language language [was was established] to to (editorial or review) [CLHTA, CLHTA,CLCMR; records were removed] 32 systematic review/or \"systematic review (topic)\"/or syste analysis/ or \"meta analysis (topic).\"from from 34",
      "start_page": 109,
      "end_page": 112
    },
    {
      "heading": "• Embase ~ updated search: 10 March 2021",
      "text": "$$$$£$$ $$ $ $$ £ $ $ $ £ £ / $ @ £ or $ ~ ~ or • or ~ $ { ~ 0 $ , $ ^ ~ 1 ~ language language c-survi survi val).ki-31465 ki-31465 AS) adj5 on$ or on$or ival* to to (or or \"review\" or or tombstone) 32 systematic review/ or \"systematic review (topic)\"/ meta-511387 meta-511387 analysis/ analysis analysis (topic).\"mp.",
      "start_page": 112,
      "end_page": 114
    },
    {
      "heading": "to to yr=\"2019 -Current' 15154",
      "text": "colon colon cancer/ rectum rectum cancer/or colorectal tumor/199364 6 ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or segmo$ or rectosigm$ or bowl$ or or anus) adj3 (cancer$ or neoplas$ or oncoog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or metastas$ or meta-sta$ or sarcoma$or adenom$or lesion$)).ti,ab.",
      "start_page": 114,
      "end_page": 114
    },
    {
      "heading": "ras ras oncogene/ 12466",
      "text": "21 ((or or k-ki-ras or c-Kirsten Kirsten RAS) adj5 (mutation$ or mutant$ or or gene$ or translocation$ or arrangement$ or oncogene$ or fusion$ or expression$ or over?expression$ or amplification$ or inversion$ or deletion$)).",
      "start_page": 114,
      "end_page": 116
    },
    {
      "heading": "Cochrane updated search: 10 March 2021",
      "text": "[ascinoma, ascinoma, Non-Small-Cell retail, Lung/ 2 (lung lung cancer).to to yr=\"2019 -Current\" [in in DARE; records were established] colon colon cancer/ or ecctum cancer/cancer cancer / or colorectal tumor/6 ((colorect$ or rectum$ or colon$ or sigma$ or signo$ or rectosign$ or or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or or adenocarcinoma$ or metasta$ or sarco$ or salom$ or lesion$)). language language [was was established] to to (editorial or review) [CLHTA, CLHTA,CLCMR; records were retarded] 32 systematic review/or \"systematic review (topic)\"/or systema analysis/ or \"meta analysis (topic).32 32 val* mp mp survival* or 105477 val).25533 25533 MR; or or Meta-33812",
      "start_page": 116,
      "end_page": 117
    },
    {
      "heading": "34 34 65",
      "text": "• with with __MEDTERM0_- and and comparison; risk risk factor; regard, regard, • Indeterminate risk (Twisting) • risk risk (an an anti-PD-(L) outcomes outcomes • Overall survival (_MEDERTM9__2) § • Progression-free survival (PFS_)§ • therapy therapy (__MIDTERM 10_2)",
      "start_page": 118,
      "end_page": 119
    },
    {
      "heading": "Safety and tolerability:",
      "text": "• AEs AEs • AEs AEs . • SAES SAES • Tolerability: discrimination discrimination (any reason), discrimination (due to AEs) Phase II • trials trials • only only • trials trials ■ Studies with < publications publications (inclusion. inclusion.) papers papers • Exclu Exclu (experimental/studio studio observational) 1) SLR Update: trials trials (to cover KRASm)",
      "start_page": 119,
      "end_page": 120
    },
    {
      "heading": "2. SLR Screen:",
      "text": "2019 2019 (to cover KRASm) comparator comparator arm) out animal/SCLCry SCLCry (systematic systematic reviews* Country Not restricted",
      "start_page": 120,
      "end_page": 121
    },
    {
      "heading": "the the SLRs",
      "text": "irrelevant irrelevant RCT'subgroup. subgroup.",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "excluded excluded RCTs",
      "text": "† patient patient (Table Table 3). mutation mutation (Table Table 4). countries. countries.",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "reliability reliability criteria",
      "text": "mg mg 1) have have 1) Patients aged ≥ 18 1) had had 1°: _PFS 2015/101) students (previous previous year; 2°: Hungary, Hungary, (n=86) previous previous years; added added >were were 2) daily daily + antiepileptic antiepileptic (n=30) 2018 2018 (104) mg mg 1) Patients of (1) Patients with 1) knowledge knowledge 1°: 1 1 patient' patients with 1) People with 1) 1 1 °: _ ---MEDERM6T01395758 2o: Still Still [...] (n=45) 2020 2020 (105) 21 21 days) mg mg 1) Patients with 1) 21 21 days), (n =45) 2020. 2020. (105] mg mg (1) Patients with1) ___medTERM64-_astatic ___medTERM64-_astatic (stage IV) __ARMM64__as __ARMM64__as (n=270) Phaseing 3 (still night IV) platinum-based platinum-based - MEDTERM464__astatic MEDTERM464__astatic (Stage IV) 2011. 2011. platinum-treatment treatment (a non-mechano Supper's honour) Patients with e/with with 1°: OSe/untreaated brain 2°: of of study; NC. NC. (n=254) any any (same schedule) docetaxel-containing 3) With WHO (n=156) __MEDTERM4_150 __MEDTERM4_150 1) to to 1) Patients aged ≥ 18 1) tumor tumor 1°: EML4-__MEDTER EML4-__MEDTER [...] 2 2 (2) of Regulation (EU) No 182/the the Commission'powers powers (p. p. 1). 107 107 (1) 2020 2020 (110) 150 150 1) had had 1) unstable unstable 1°: satisfied satisfied mg/NC01798485 NC01798485 2°: NCT02008227 NCT02008227 2°: and and (n=425) A A NCT082272°: __MIDTERM65_, [N=4255] an an ---met_assis met_assis mg/excluded excluded (n=179) 2015 2015 (114) mg mg 1) had had 1) clinically clinically 1°: __ENTERTM66_ STY (orally orally + received 1 •NCT01244191 NCT01244191 2°: sugar-canned sugar-canned sugar-cake-and-sugar-cane syrup-to-poor sugar-in-the-market sugar- content content (n) median, (%) n (%) Name Name (n = = n=== n] n [N=103) n n (%) p p (%) NCT ID, (n), n (%) i i n) median; n (%) y y (all all , n % PD-L1 KRAS (n (%) c c (%) Nct) u u . __MEDTERM35_u __MEDTERM35_u (36) Current: 0 (0) 0 (0) - - - KRASm: 11 (100) (n=11) (50 responsibility83) Forms: 11 KRASSmG12C: 4 (36), NCT01229150; (100) Excluded CTEP: 2 2 __MIDTERM7__+ 66 14 (47) Current: 9 (30) - -- KRASMm: 30 (100) comparators __MEDARM3_ (58-82) Shapes: 21 (70) KRASFmG2C: 8 (27) (n=30) ___MEDTERM7_ ___MEDTERM7_ + 64 18 (35) Curent: 3 (6) -- -- n° workers. workers.",
      "start_page": 123,
      "end_page": 135
    },
    {
      "heading": "Local adaptation",
      "text": "studies studies • December December 2019: 4 14 PD-[L]1 therapies) brain brain metastases; antitumour antitumour Secondary: pk, __MEDTERM67_03; whole. whole. (b ≥ 3: 20 (100) N N CHT: 20 (100), metastatic solid BEV: 10 (50) tumors; standard of Nivolumab_: 1 (5) or or TKI: 19 (95) inappropriate; __medterm15____: 1 (5), ≥ 20 years old; ECOG ErlotinibS: 10-50) PS ≤ 2; no significant __medterm17__= 13 (65) comorbidityes. __midterm18__-: 1 (20) __MIDTERM66__^expansion: MEDTERMM66__ MEDTERMM66__ (IIIb or IV); v1. v1.0; the the following: _EGFRUTE (__MEDARM50_ __MEDARM50_ inhibitor); KRASm; Kingdom Kingdom - Median Median (Range), Endpoints/n n (%) and and 1:16 (29.6) NR NR Primary: ___MEDTERM20_ ___MEDTERM20_ 2: 38 (70.4) KRASAm subtype; __MEDARM66___ SECONDARY: or or recurrent; Regulation Regulation (EU) No 1239/Union Union (p. p. 671). risk, risk, risk/benefit/risk/risk-of-security risk/loss/losses of risk/risk_risk/loss_risk_capital_risks/risks_risk &amp; equity_risk=risk/107 107 (3) (c) concomitant concomitant Primary: dose finding nt: Oct sorafenibSurgery: 1 (0 - 4) (NSCLCuncontrolled NSCLCuncontrolled Secondary: 16 16 Radiation: 1 (0.4) with KRASm); conditioning; 2013 2013 CHT: 2.5 (0-6) Targeted Targeted therapy: v1. v1.1; permanently permanently (0.2) PS 0 - 107 107 (1) Union Union (TFEU) __MIDTERM38_3 __MIDTERM38_3 (0 - 11) or or 1; active active Primary: Cohort Cohort A: NR NR Primary: pembrolizumabCohort pembrolizumabCohort B: 68% with with ≥ 1% KRASm KRASm non- and non-SAEs (__midTERM66_United __midTERM66_United Kingdom: ___MEDERTSB68_IN ___MEDERTSB68_IN Crombet; Autophagy Autophagy Inhibitions: n n (%) NR NR Primary: NR NR ed: Oct 153 CHT: 25 25 (73.5) 22 22 (78.6) All __ENTERTM66__; ≥ 2 LOTs, Secondary: 92 92 (60.1) PK PK Hormonestheapy: soorasib. soorasib.",
      "start_page": 135,
      "end_page": 153
    },
    {
      "heading": "Local adaptation:",
      "text": "future. future.",
      "start_page": 153,
      "end_page": 154
    },
    {
      "heading": "local local adaptation",
      "text": "Ø Ø +00 00 medicieraadet@Proprietary Proprietary - of of 1) Patients 18 1) Mixed 1°: had had 2°: and and non",
      "start_page": 154,
      "end_page": 156
    },
    {
      "heading": "Quality assessment",
      "text": "methodology. methodology.",
      "start_page": 156,
      "end_page": 156
    },
    {
      "heading": "Unpublished data",
      "text": "to to EMA/Page Page 150/Ø Ø +00 00 medicraadet@B B - Table 39: Trial Trial name: Publications Publications • 1 1 (to to 5). • response response • rate rate (1. 1.1; 5 5 weeks) • Overall survival • Progress-free survival ■ secondary secondary endpoints: • Safety • 0. 0.",
      "start_page": 156,
      "end_page": 159
    },
    {
      "heading": "Table 40: SELECT-1 • Study Characteristics",
      "text": "Ø Ø +00 00 medicraadet@Compar Compar Medicinsråe: criteria criteria rator(eria eria s) Proprietary Proprietary - NCT NCT number: NCT01933932 Main inclusion: • procedures procedures • older older • ___ ___ (IIIB-IV) • laboratory laboratory • radiological radiological disease",
      "start_page": 159,
      "end_page": 160
    },
    {
      "heading": "Main exclusion:",
      "text": "• surgery. surgery. • Received >therapy therapy (first-line first-line regimen) reliable. reliable. • 75 75 mg/factor factor (G-CSF) G-CSF G-CSF (pegfilgrastim) toxicity. toxicity.",
      "start_page": 160,
      "end_page": 161
    },
    {
      "heading": "Health economic model?",
      "text": "Proprietary Proprietary - NCT NCT number: overall overall survival: placebo + months months (progression-free progression-free survival: Placebo + months months (03-11. 03-11.1) Outcome Outcome Variables: 1. 1.1",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "Secondary Outcome Variables:",
      "text": "Index Index (ASBI) Scale Scale (LCSS) The The LCSS",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "Safety:",
      "text": "• Advise events • urinalysis urinalysis • Vital signs • ECHO/MUGA • Ophthalmological examination",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "Exploratory Outcome Variables:",
      "text": "• levels levels • results results • discrimination discrimination • kras mutation subtype(s) • polymorphismsms polymorphismsms • Ø Ø +00 00 medicineraadet@medicintraadet.dk (de de 155/diciner diciner me: Proprietary Proprietary - 80 80 (__MIDTERM5__ __MIDTERM5__ events).an an intention-interval interval (CI), Kaplan-Meier Kaplan-Meier (KM) represented. represented. • randomization randomization (< 65 vs. = 65) • Smoking status (non-smokers non-smokers (never smoker) ● disease disease (vs. vs. Metastatic) II II (D1532C00016) effect. effect.",
      "start_page": 161,
      "end_page": 163
    },
    {
      "heading": "information information None",
      "text": "• assets assets (CodeBreak-1) criteria criteria • Adults (age ≥ 18 years) • Adults (age > 18 years), • locally locally • Histologically/metastatic metastatic (stage IIIB - or or IV) NSCLC Metastatic ( stage IIIB-IV) ___MEDTERM 2_____ECOG/1 1 • ADOG/ or or • to to KRA'Ø Ø +00 00 medicieradet@Proprietary Proprietary - C C - a a (CodeBreak 100) N = 126 Age (mean) Gender Gender (% female) 50% Brain metastases (%) 21% ECOG (% PS 1 [vs PS 0]) 70% Race (% white) 82%c % KRAS-G12C 100% Anti-PD-(L) prior prior line(s) 91% lines lines (% with 1/2/3 senior lines).",
      "start_page": 163,
      "end_page": 164
    },
    {
      "heading": "across across studies",
      "text": "studies. studies.",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "for for treatment",
      "text": "2. 2.",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "outcome outcome measures",
      "text": "2 2 (7) Regulation. Regulation.",
      "start_page": 164,
      "end_page": 166
    },
    {
      "heading": "Results per study",
      "text": "following following data: http://europa.eu.int/comm/dgl/index_en.htm",
      "start_page": 166,
      "end_page": 167
    },
    {
      "heading": "X",
      "text": "0 0 (NA NA * ary ary - Ø Ø +NA NA *cut-off cut-off 2021(7 in 3) March NA *Cut-off Cut-off 2022(7in3) March NA*data data file(75) March March NA",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "X",
      "text": "Page 161/237 adet@Am Am , tary tary - Ø Ø +medicierra medicierra aadet@x X X",
      "start_page": 167,
      "end_page": 168
    },
    {
      "heading": "X",
      "text": "Proprietary Proprietary - Ø Ø +medicinsra medicinsra aadet@Page Page 163/Proprietive Proprietive - Copenhagen Copenhagen Ø+medikra medikra aadet@@medici inraade",
      "start_page": 169,
      "end_page": 170
    },
    {
      "heading": "Page 164/237",
      "text": "Proprietary Proprietary - Ø Ø +mediciera mediciera aadet@@medici inraade",
      "start_page": 170,
      "end_page": 171
    },
    {
      "heading": "Page 165/237",
      "text": "N N = analysis analysis set; n = Proprietary Proprietary - observed observed data; SD = Ø Ø +deviation deviation aadet@medici n inraade",
      "start_page": 171,
      "end_page": 172
    },
    {
      "heading": "Page 166/237",
      "text": "NCE01933932) __medterm0_____medrm0_ __medterm0_____medrm0_ (___medtermo__dsk ___medtermo__dsk + o o + N(%) 9 9 (5. 5.9) SELECT-1 SELECT-1 (NCT019 Lect-1 (NCT0193332) 9 9 (5. 5.9) 8 8 (2 2 . A A , CT-1 CT-1 (T T ABSI: asib asib (tary tary - co co CodeBreak-100)* n=126 Grade 3+ vn Ø +nly nly arator(s) Docetaxel + NA NA NA",
      "start_page": 172,
      "end_page": 176
    },
    {
      "heading": "adverse adverse events",
      "text": "waywaywaywayswaywaywardwaywaythroughwaywayhomewaywaymarketwaywayspacewaywaywellwaywayourwaywaygroundwaywayallwaywayholewaywayotherwaywaybywayway waywaywaywayswaywaywardwaywaythroughwaywayhomewaywaymarketwaywayspacewaywaywellwaywayourwaywaygroundwaywayallwaywayholewaywayotherwaywaybywayway (54.8) 16 16 (12.7) 12 12 (9.5) 6 6 (4.8) 5 5 (4.0) 5 5 (4.5) 0 0 (0) 2 2 (1.6) 3 3 (2.4) 0 0 (0) disorder disorder 0+ 4 4 (3.2) Footnote: reported reported . hard hard - U U CodeBreak-100)* Grade 3+ vn +Docetaxel Docetaxel + p n= Any Grade edicinraadet@o o (SELECT-1) Grade 3 + de de 171/Proprietary Proprietary - 8 8 (6.3) 0 (0) Heache 11 (8.7) 0 (0) Myalgia 8 (6.3) 0 (0) Footnote: in in >10% 48 48 (3 3 6), 8 8 (63) 0 (0) th. th.",
      "start_page": 176,
      "end_page": 181
    },
    {
      "heading": "from from SELECT-1",
      "text": "Ø Ø +mediciera mediciera aadet@@Page Page 175/Proprietary Proprietary - Use Use Only",
      "start_page": 181,
      "end_page": 182
    },
    {
      "heading": "X X X",
      "text": "grade grade 3+ economic economic analysis? Grade 3+ CodeBreak 100 16% (61%- 35. 35.5% events events & SELECT-1 45%) 100 100 -5.8% (8.7%- NA 40% no no & Select-1 14.5%) AEs AEs ((14.5%-- NA 40) AUS AUS ((13.5%-",
      "start_page": 182,
      "end_page": 182
    },
    {
      "heading": "Appendix G - Extrapolation",
      "text": "of of time-to-event data.",
      "start_page": 182,
      "end_page": 182
    },
    {
      "heading": "X *population population (N =126)",
      "text": "Page 176/Ø Ø +36 36 00medicinsraadet@medicinraadet.dk",
      "start_page": 182,
      "end_page": 182
    },
    {
      "heading": "X",
      "text": "*Proprietary Proprietary - population population (N =123) ndix H - I I - Ø Ø +medicinera medicinera aade@@Side Side 177/Proprietary Proprietary - J J - all all data/parameters. parameters.",
      "start_page": 183,
      "end_page": 184
    },
    {
      "heading": "X X X",
      "text": "Ø Ø +00 00 medicraadet@values values alysis",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "Page 178/237",
      "text": "et.dk",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "X",
      "text": "Steamfae Steamfae Ergevej",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "X",
      "text": "Pr. Pr.",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "X",
      "text": "roprietary roprietary - F",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "X",
      "text": "benhavn Ø + For Internal U",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "X",
      "text": "me me nly",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "X X",
      "text": "edicinraadet@de de 179/237 medicinadet.dm",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "X",
      "text": "Steamfae Steamfae Ergevej",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "X",
      "text": "Pr. Pr.",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "X",
      "text": "roprietary roprietary - F",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "X",
      "text": "benhavn Ø + For Internal U",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "X",
      "text": "me me nly",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "X X",
      "text": "edicinraadet@de de 180/237 medicinadet.dm",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "X",
      "text": "Proprietary Proprietary - Use Use Only",
      "start_page": 187,
      "end_page": 187
    },
    {
      "heading": "X X X",
      "text": "Ø Ø +00 00 medicraadet@et. et.dk",
      "start_page": 187,
      "end_page": 187
    },
    {
      "heading": "Page 181/237",
      "text": "Amgen Proprietary - Use Use Only",
      "start_page": 188,
      "end_page": 188
    },
    {
      "heading": "Data Data sources",
      "text": "interest. interest.",
      "start_page": 188,
      "end_page": 188
    },
    {
      "heading": "data data sources",
      "text": "the the Commission'2 2 (1) Regulation. Regulation.",
      "start_page": 188,
      "end_page": 189
    },
    {
      "heading": "Endpoint",
      "text": "assessed assessed PFS; __MIDTERM1__",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "endpoints",
      "text": "PFS_ PFS_ Key: oncology oncology group; protein protein kinase; lung lung cancer; response response rate; ~MEDTERM2_, overall survival; }MEDTERMI_, progression-free survival; factor factor receptor; __MIDTERM3_ __MIDTERM3_ (Stage IIIB",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "investigators investigators in",
      "text": "Ø Ø +00 00 medicieradet@Proprietary Proprietary - Gender Gender (% female) 50% 43% Brain metastases (%) 21% status status (ECOG or WHO; 70% 59% % PS 1 [vs PS 0]) Race (% white) 82%d 95% % KRAS G12Cmutated 100% 42%b Anti-PD-(L) prior prior line(s) 91% 0% lines lines (% with 1/2/3 43%/35%/22% 100%/0%/0% senior lines) baseline baseline 96% 96% Histology (% Non-squamous) 99% 95% Smoking status (% ever smoker) 93%e 92% mutations mutations (_MEDTERM2__, 3% BRAF, BRAF, ROS-1) baseline baseline (< 5% 48%",
      "start_page": 189,
      "end_page": 190
    },
    {
      "heading": "indirect indirect comparisons",
      "text": "included included 57% Page Page 184/Ø Ø +of of therapy; conservative. conservative.",
      "start_page": 190,
      "end_page": 191
    },
    {
      "heading": "of of weights",
      "text": "concerned. concerned.",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "rescaled rescaled weights",
      "text": "following following formula: size size (ESS). unstable. unstable.",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "sample sample size",
      "text": "the the ESS:",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "incorporating incorporating weights",
      "text": "107 107 (1) groups groups <5% and ≥ 5% only; physicians. physicians.",
      "start_page": 191,
      "end_page": 192
    },
    {
      "heading": "in in MAIC",
      "text": "2 2 (3. 3.1) used. used.",
      "start_page": 192,
      "end_page": 192
    },
    {
      "heading": "2 2 • available available covariates",
      "text": "case. case.",
      "start_page": 192,
      "end_page": 192
    },
    {
      "heading": "X X X",
      "text": "survival. survival.. only. only. a: Investigator, b: Page Page 186/Ø Ø +00 00 medicierraadet@Proprietary Proprietary - Use Use Only",
      "start_page": 192,
      "end_page": 193
    },
    {
      "heading": "SET SET 2",
      "text": "N N = 256 N = ECOG ECOG (% PS) 1 [Age Age (mean) baseline baseline (%) Smoking status (% ever ever smoker) level level (<5% vs ≥ 5%) Gender (% female) x Histology (% Non- x x squalous) Ø Ø +medicine medicine aadet@ n n = Side Side 187/237 @Proprietary Proprietary - Race Race (% white)",
      "start_page": 193,
      "end_page": 194
    },
    {
      "heading": "Overall Overall survival",
      "text": "Hi5G2g Hi5G2g rightway!H2Aright rightowowowing.Hash-of-and and log-log-loggistic. Goodness-of‐Fit Fit (unrestricted and restricted) 58. 58. _OSGoodness-matched matched (fit fit .fit fit - Jointfit 58.",
      "start_page": 194,
      "end_page": 195
    },
    {
      "heading": "Page 189/237",
      "text": "Proprietary Proprietary - Use Use Only",
      "start_page": 195,
      "end_page": 196
    },
    {
      "heading": "SET SET 2",
      "text": "Key: indirect indirect comparison; survival. survival.",
      "start_page": 196,
      "end_page": 196
    },
    {
      "heading": "SET SET 2",
      "text": "Key: indirect indirect comparison; Ø Ø +medicera medicera aadet@@medici inraade",
      "start_page": 196,
      "end_page": 196
    },
    {
      "heading": "Page 190/237",
      "text": "Proprietary Proprietary - in in Error! found. found..",
      "start_page": 196,
      "end_page": 197
    },
    {
      "heading": "X",
      "text": "Key: Doc, docetaxel; KM, Kaplan-Meier; indirect indirect comparison; OS, overall survival; Sot, sotorasib.",
      "start_page": 197,
      "end_page": 197
    },
    {
      "heading": "Progression-free Progression-free survival",
      "text": "14. 14.",
      "start_page": 197,
      "end_page": 198
    },
    {
      "heading": "SET SET 2",
      "text": "Key: indirect indirect comparison; survival. survival.",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "SET SET 2",
      "text": "Key: indirect indirect comparison; Ø Ø +medicinera medicinera aadet@@medici inraade",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "Page 192/237",
      "text": "Proprietary Proprietary - Use Use Only",
      "start_page": 198,
      "end_page": 199
    },
    {
      "heading": "SET SET 2",
      "text": "Key: indirect indirect comparison; in in Error! found. found..",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "X",
      "text": "Key: Doc, docetaxel; KM, Kaplan·Meier; indirect indirect comparison; __MEDTERM0_, progress",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "MAIC MAIC analysis",
      "text": "2 2 (1) of Regulation (EU) No 575/2013. • overlap overlap (_MEDTERM0_, anti-prior prior lines) data data (% patients. patients. • metastases metastases (brain brain metases) was was 21% years. years.",
      "start_page": 199,
      "end_page": 201
    },
    {
      "heading": "score score analysis",
      "text": "25,9$$$===%== %==#==[%=%&%= ###=###[*]##_[[[-[-][- [-]#[- ]#[[ -][[S][ -[-T][A]][ [-[B]]] _ [- [S] , [- (S] - [T] - ...[- and [- S] - [...] - [- ] - [[- T] -[S ] -[G] -",
      "start_page": 201,
      "end_page": 202
    },
    {
      "heading": "Index Index date",
      "text": "as as follows: • received received ≥ 2 but ≤ theory theory on/selected. selected. • lines lines on/2020. 2020.",
      "start_page": 202,
      "end_page": 202
    },
    {
      "heading": "Analysis Analysis sets",
      "text": "were were considered: Page Page 196/Ø Ø +00 00 mediceraadet@Proprietary Proprietary - time time on/CodeBreak. CodeBreak.",
      "start_page": 202,
      "end_page": 203
    },
    {
      "heading": "expert expert elicitation",
      "text": "presented presented (Table 61). Page 197/Ø Ø +36 36 00medicinraadet@Proprietary Proprietary - Use Use Only",
      "start_page": 203,
      "end_page": 204
    },
    {
      "heading": "Covariate Include (Y/N) Adjustment",
      "text": "baseline baseline (Y; N) were were lower; expression expression (<1%, 1-49%, <50%) No PD- anti anti PD-(L)with with anti-sheet. sheet.",
      "start_page": 204,
      "end_page": 204
    },
    {
      "heading": "Page 198/237",
      "text": "Ø Ø +36 36 00medicinraadet@Proprietary Proprietary - Use Use Only",
      "start_page": 204,
      "end_page": 205
    },
    {
      "heading": "patient patient disposition",
      "text": "presented presented (Error! found. found.).",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "baseline baseline characteristics",
      "text": "mutant mutant (Error! Figure Figure 20).",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "X X X",
      "text": "Ø Ø +36 36 00medicinraadet@idea idea 199/237 et.dm",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "X",
      "text": "etary etary - Ø Ø + Use Use Only",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "X",
      "text": "+y y dicinraad",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "X",
      "text": "it@medicra aadet.dk",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "X",
      "text": "idea idea 200/237 et.dk",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "X",
      "text": "etary etary - Use Use Only",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "X",
      "text": "avn Ø +with with y",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "X",
      "text": "dicinraad",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "X",
      "text": "it@medicra aadet.dk",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "X",
      "text": "idea idea 201/237 et.dk",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "X",
      "text": "etary etary - Use Use Only",
      "start_page": 208,
      "end_page": 208
    },
    {
      "heading": "X",
      "text": "avn Ø +y y dicinraad",
      "start_page": 208,
      "end_page": 208
    },
    {
      "heading": "X",
      "text": "it@medicra aadet.dk",
      "start_page": 208,
      "end_page": 208
    },
    {
      "heading": "X",
      "text": "idea idea 202/Proprietary Proprietary - Use Use Only",
      "start_page": 208,
      "end_page": 209
    },
    {
      "heading": "KRAS KRAS mutant",
      "text": "Key: mass mass index; DUR, duration; Oncology Oncology Group; ETHN, metastatic; PREV, previous Note: for for binary/of of > 10% Ø Ø +00 00 medikraad",
      "start_page": 209,
      "end_page": 209
    },
    {
      "heading": "X X",
      "text": ", ethnicity; GRP, group; for for det@Page Page 203/Proprietary Proprietary - Use Use Only",
      "start_page": 209,
      "end_page": 210
    },
    {
      "heading": "Flatiron Flatiron KRAS-G12C",
      "text": "Key: mass mass index; DUR, duration; Oncology Oncology Group; ETHN, ethnicity; GRP, group; __MEDTERM0_, metastatic; PREV, previous Note: for for binary/of of > 10% considered impaired",
      "start_page": 210,
      "end_page": 210
    },
    {
      "heading": "analysis analysis methods",
      "text": "analysis. analysis.",
      "start_page": 210,
      "end_page": 210
    },
    {
      "heading": "CodeBreak CodeBreak 100",
      "text": "107 107 (3) (c) Treaty. Treaty.",
      "start_page": 210,
      "end_page": 211
    },
    {
      "heading": "in in Flatiron",
      "text": "__MEDTERM0_ __MEDTERM0_ (rw_MEDTERM0__) report. report.",
      "start_page": 211,
      "end_page": 211
    },
    {
      "heading": "Covariates",
      "text": "physicians physicians (76). interviewed interviewed (oncsists oncsists interviewed): • Baseline ECOG (0 or 1) • metastases metastases (Y; N) • baseline baseline (Y); N) Ø Ø +00 00 medicraadet@idea idea 205/Proprietary Proprietary - Only Only • date date (<6 6 months) • baseline baseline • Liver function (ALT, AST) at baseline",
      "start_page": 211,
      "end_page": 212
    },
    {
      "heading": "Analysis Analysis methods",
      "text": "problem. problem.",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "Analysis set",
      "text": "criteria criteria included: • __MEDTERM0_A __MEDTERM0_A • an an anti-PD(L)anti anti PD-(L),lines, lines, • Baseline ECOG ≤ other other non-time time on/the the patient's decision.",
      "start_page": 212,
      "end_page": 213
    },
    {
      "heading": "Statistical Statistical methods",
      "text": "as as follows: weight. weight.",
      "start_page": 213,
      "end_page": 213
    },
    {
      "heading": "model model development",
      "text": "AIC AIC (to be limited) information. information.",
      "start_page": 213,
      "end_page": 213
    },
    {
      "heading": "Balance diagnostics",
      "text": "following following criteria:",
      "start_page": 213,
      "end_page": 214
    },
    {
      "heading": "adjustment adjustment method",
      "text": "applied applied (136, 137). weight weight scores: treated treated (sotorasib) equivalent. equivalent.",
      "start_page": 214,
      "end_page": 214
    },
    {
      "heading": "Effective sample size",
      "text": "size size (ESS). as as follows: ESS = . Ø Ø +mediciner mediciner Vervad@endraformik.",
      "start_page": 214,
      "end_page": 215
    },
    {
      "heading": "Missing values",
      "text": "information information (n=7), presented presented (Table 62). (g/l) 1 (0.8) BMI (kg/m2) n (%) 11 (0.0.8) n (%) 85 (37.8) 1 (0.8) 1 (0.8) n % n (%) 12 (5.3) 1 (0.3) n (%) 7 (3.3) 1 (0.1) 3 (2.4) Smoking history",
      "start_page": 215,
      "end_page": 216
    },
    {
      "heading": "Efficacy Efficacy results",
      "text": "weighting weighting (Figure 23), balanced. balanced.",
      "start_page": 216,
      "end_page": 216
    },
    {
      "heading": "Key: None",
      "text": "Weighting Weighting Key: Side Side 210/Ø Ø +36 36 00medicinraadet@Proprietary Proprietary - good good (Figure Figure 25). as as •outliers",
      "start_page": 216,
      "end_page": 217
    },
    {
      "heading": "Key: None",
      "text": "Weighting Weighting Key: Page Page 211/Ø Ø +00 00 medikraadet@Proprietary Proprietary - 26. 26.",
      "start_page": 217,
      "end_page": 218
    },
    {
      "heading": "Analysis Analysis Set",
      "text": "Key: differences differences >0.1; p-value p-value < Page Page 212/Ø Ø +00 00 medicineraadet@Proprietary Proprietary - limited limited (99.5% v. v.",
      "start_page": 218,
      "end_page": 219
    },
    {
      "heading": "sample sample size",
      "text": "mutation mutation (any type) 206 206 (adjuvanted adjuvanted (Table 63). 85 85 (unaided) Sotorasib Sotorasib KRA'Adjusted Adjusted (ATT) 104.8 119",
      "start_page": 219,
      "end_page": 219
    },
    {
      "heading": "G12C",
      "text": "Adjusted Adjusted (ATT) 119 119 Key: the the treated",
      "start_page": 219,
      "end_page": 219
    },
    {
      "heading": "analysis analysis results",
      "text": "Flatiron Flatiron KRA",
      "start_page": 219,
      "end_page": 219
    },
    {
      "heading": "mutation. mutation.",
      "text": "(Figure Figure 29), Model 2 (Figure Figure 31) 3 3 (Figure Figure 33). Ø Ø +00 00 medicierraadet@ely ely ed) ide ide 213/Proprietary Proprietary - Use Use Only",
      "start_page": 219,
      "end_page": 220
    },
    {
      "heading": "Flatiron Flatiron KRAS G12C",
      "text": "Key: mass mass index; DUR, duration; Oncology Oncology Group; ETHN, ethnicity; GRP, group; __MEDTERM0_, metastatic; PREV, previous Note: for for binary/of of > 10% considered impaired",
      "start_page": 220,
      "end_page": 220
    },
    {
      "heading": "KRAS KRAS Mutant",
      "text": "Key: mass mass index; DUR, duration; Oncology Oncology Group; ETHN, ethnicity; GRP, group; __MEDTERM0_, metastatic; PREV, previous Note: for for binary/of of > 10% Ø Ø +www. www.medic",
      "start_page": 220,
      "end_page": 220
    },
    {
      "heading": "Page 214/237",
      "text": "Proprietary Proprietary - Use Use Only",
      "start_page": 220,
      "end_page": 221
    },
    {
      "heading": "Flatiron Flatiron KRAS G12C",
      "text": "Key: mass mass index; DUR, duration; Oncology Oncology Group; ETHN, ethnicity; GRP, group; __MEDTERM0_, metastatic; PREV, previous Note: for for binary/of of > 10% Mutant Mutant Key: Body Mass Index; DU, Duration; Cooperation Cooperation Unit; ETHN, ethnicity; GRP, group",
      "start_page": 221,
      "end_page": 221
    },
    {
      "heading": "Page 215/237",
      "text": "Proprietary Proprietary - Use Use Only",
      "start_page": 221,
      "end_page": 222
    },
    {
      "heading": "Flatiron Flatiron KRAS G12C",
      "text": "Key: mass mass index; DUR, duration; Oncology Oncology Group; ETHN, ethnicity; GRP, group; __MEDTERM0_, metastatic; PREV, previous Note: for for binary/of of > 10% Mutant Mutant Key: Body Mass Index; DU, Duration; Cooperation Cooperation Unit; ETHN, ethnicity; GRP, group",
      "start_page": 222,
      "end_page": 222
    },
    {
      "heading": "Page 216/237",
      "text": "Proprietary Proprietary - Use Use Only",
      "start_page": 222,
      "end_page": 223
    },
    {
      "heading": "using using Flatiron",
      "text": "MAC MAC analysis: (i) anti anti PD-(L)landscapes landscapes (ii) adjustment. adjustment.",
      "start_page": 223,
      "end_page": 223
    },
    {
      "heading": "Flatiron Flatiron database",
      "text": "2 2 (1) of Regulation (EU) No 182/the the Commission'Regulation. Regulation.",
      "start_page": 223,
      "end_page": 224
    },
    {
      "heading": "analysis analysis results",
      "text": "important important , default default (altars altars (or or ROS-1)), the following •price price , selection selection procedure: baseline. baseline.",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "ECOG: 1 74.27% 70.59% 70.46%",
      "text": "Gain of metastasic_property: Yes 28.16% 20.89% 92. 92.72% 97.48% 97.88% Presence of __MEDTERM0_/_MEDTERM1_/BRAF/8. 8.25% 3.36% 3.43% Age (categories) 43. 43.20% 52.10% 50.82% 33. 33.98% 39.50% 41.02% ≥ 22. 22.82% 8.40% 8.15% Ø Ø +00 00 medicraadet@ide ide 218/Proprietary Proprietary - Prior Prior PD-(L) 1 immunotherapy: Yes 73.30% platinum-based platinum-based chemotherapy: Yes 84.47% 89.08 Alminaft; Ø Ø +00 00 medicraadet@Gro Gro -for for cant",
      "start_page": 224,
      "end_page": 226
    },
    {
      "heading": "comparator comparator cohort",
      "text": "chemotherapy chemotherapy (from 31.07% to 23.04% main main •KRA mutant^ analysis), ramucirumab ramucirumab (fro 21.84% to 34.20% in the KRA's mutant",
      "start_page": 226,
      "end_page": 226
    },
    {
      "heading": "(N = 206) (N= 120.57)",
      "text": "31. 31.07% 23. 23.04% Chemotherapie monotherapy (including docetaxel) 61 29.61% 26. 26.94% 21. 21.84% 34. 34.20% 10. 10.19% 10. 10.09% 7. 7.28% 5. 5.73%",
      "start_page": 226,
      "end_page": 226
    },
    {
      "heading": "(N = 85) (N= 133.11)",
      "text": "29. 29.41% 17. 17.90% Chemotherapy monotherapy (excluding docetaxel) 24 28.24% 22. 22.85% 21. 21.18% 48. 48.21% 12. 12.94% 6. 6.43% 8. 8.24% 4. 4.61% Ø Ø +00 00 medicieraadet@ide ide 220/Proprietary Proprietary - Use Use Only",
      "start_page": 226,
      "end_page": 227
    },
    {
      "heading": "2 2 Results",
      "text": "p. p.G12C",
      "start_page": 227,
      "end_page": 227
    },
    {
      "heading": "HR (95% CI) G12C G12C only",
      "text": "Cohort.",
      "start_page": 227,
      "end_page": 227
    },
    {
      "heading": "Overall Overall survival",
      "text": "14 14 (88). fitting fitting (restricted restricted models) R R (0. 0.3) between between .of of goodness-distribution distribution (Table 67). States. States.",
      "start_page": 227,
      "end_page": 228
    },
    {
      "heading": "X",
      "text": "valid. valid.",
      "start_page": 228,
      "end_page": 229
    },
    {
      "heading": "and and Control",
      "text": "Key: survival. survival.",
      "start_page": 229,
      "end_page": 229
    },
    {
      "heading": "and and Control",
      "text": "Key: Ø Ø +dicinraad dicinraad det@w. w.medic",
      "start_page": 229,
      "end_page": 229
    },
    {
      "heading": "Page 223/237",
      "text": "Proprietary Proprietary - Use Use Only",
      "start_page": 229,
      "end_page": 230
    },
    {
      "heading": "and and Control",
      "text": "Key: fitted fitted (restrictive model) dataset. dataset.",
      "start_page": 230,
      "end_page": 230
    },
    {
      "heading": "Progression-free Progression-free survival",
      "text": "14 14 (88) fitting fitting (restricted restricted model) R R (0. 0.3) and and log-of of goodness-of-fit statistics (finished finished models) carrier carrier (Table 68). data. data.",
      "start_page": 230,
      "end_page": 231
    },
    {
      "heading": "X",
      "text": "plots plots (plot plot (Figure 38). plot plot (Figure 39). Control Control Key: survival. survival.",
      "start_page": 231,
      "end_page": 232
    },
    {
      "heading": "and and Control",
      "text": "Key: survival. survival.",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "and and Control",
      "text": "Key: Ø Ø +dicinraad dicinraad det@w. w.medic",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "Page 226/237",
      "text": "Proprietary Proprietary - monotherapy monotherapy (Flutiron Flutiron real-worth",
      "start_page": 232,
      "end_page": 233
    },
    {
      "heading": "at at X) indicating indicating that",
      "text": "treatment. treatment.",
      "start_page": 233,
      "end_page": 233
    },
    {
      "heading": "X",
      "text": "Ø Ø +36 36 00medicinraadet@idea idea 227/Proprietary Proprietary - Use Use Only",
      "start_page": 233,
      "end_page": 234
    },
    {
      "heading": "X",
      "text": "Key: treated treated Note: each each arm",
      "start_page": 234,
      "end_page": 234
    },
    {
      "heading": "Progression-free Progression-free survival",
      "text": "KRAS KRAS mutant~ in in Error! and and Error! found found . Cox Cox proportion",
      "start_page": 234,
      "end_page": 234
    },
    {
      "heading": "and and X) adjustment, adjustment, indicatin",
      "text": "PFS PFS (ATT ATT weighting).Ø Ø +00 00 medicierraadet@Side Side 228/Proprietary Proprietary - Use Use Only",
      "start_page": 234,
      "end_page": 235
    },
    {
      "heading": "X",
      "text": "Key: treated treated Note: Ø Ø +arm arm det@Side Side 229/Proprietary Proprietary - Use Use Only",
      "start_page": 235,
      "end_page": 236
    },
    {
      "heading": "Overall Overall survival",
      "text": "explorery explorery •p.G12C-only • in in Error! and and Error! notfound. notfound., mutant mutant • Cox Cox proportion",
      "start_page": 236,
      "end_page": 236
    },
    {
      "heading": "sotorasib sotorasib productions",
      "text": "treatment. treatment.",
      "start_page": 236,
      "end_page": 236
    },
    {
      "heading": "X",
      "text": "Ø Ø +00 00 medicieraadet@Side Side 230/Proprietary Proprietary - Use Use Only",
      "start_page": 236,
      "end_page": 237
    },
    {
      "heading": "X",
      "text": "Key: treated treated Note: each each arm",
      "start_page": 237,
      "end_page": 237
    },
    {
      "heading": "Progression-free Progression-free survival",
      "text": "the the .in in Error! and and Error! main main •KRAS mutant^ Cox Cox proportion",
      "start_page": 237,
      "end_page": 237
    },
    {
      "heading": "sotorasib sotorasib produce",
      "text": "PFS PFS (statistically statistically significant).Ø Ø +Page Page 231/Proprietary Proprietary - Use Use Only",
      "start_page": 237,
      "end_page": 238
    },
    {
      "heading": "X",
      "text": "Key: treated treated Note: Ø Ø +arm arm det@Side Side 232/Proprietary Proprietary - Use Use Only",
      "start_page": 238,
      "end_page": 239
    },
    {
      "heading": "estimate estimate EQ-values values using",
      "text": "trial trial (as as monotherapy), measures measures (PROMs): EORTC QLQ-",
      "start_page": 239,
      "end_page": 239
    },
    {
      "heading": "PGIS, PGIS, EQ-are are required",
      "text": "economic economic modelling; subgroups. subgroups.",
      "start_page": 239,
      "end_page": 239
    },
    {
      "heading": "Study 20170543 (CodeBreak 100)",
      "text": "and and safety/as as monotherapy",
      "start_page": 239,
      "end_page": 239
    },
    {
      "heading": "PROM assessments",
      "text": "this this study: PIGIS, PIGIS, EQ-",
      "start_page": 239,
      "end_page": 239
    },
    {
      "heading": "PRO-CTCAE. PRO-CTCAE.",
      "text": "cycle cycle (cycle length: 21 days) visit. visit.",
      "start_page": 239,
      "end_page": 239
    },
    {
      "heading": "EQ-5D-5L",
      "text": "5 5 dimensions: activities, activities, pain/discomfort, and anxiety/of of responses: problems. problems.",
      "start_page": 239,
      "end_page": 239
    },
    {
      "heading": "Score Score (VAS): The last EQ-on on a",
      "text": "as as \"can can imaginable' as as \"can can imagine'.• of of ...Ø Ø +00 00 medicraadet@idea idea 233/Proprietary Proprietary - difference difference (MID) patients patients (139,",
      "start_page": 239,
      "end_page": 240
    },
    {
      "heading": "utility utility scores",
      "text": "The EQ-values values (or or tariffs) each each dimension",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "EQ-5D-5L Denmark Index",
      "text": "Denmark Denmark EQ-5D-5L value set(86). 1 1 (full health) to -0.757 (worse than death). Denmark Denmark index; MID MID (UK Index: 0.08) MID. MID.",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "of of interest",
      "text": "status status (pre- and",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "post-progress response), tumour response (cycle cycle 3), status, status,",
      "text": "as as follows:",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "Progression status",
      "text": "definition. definition.",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "used. used. EQ-5D-5L ratings were",
      "text": "of of EQ-missing. missing.",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "ECOG score",
      "text": "of of EQ-5D-5L assessment within",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "coded coded as",
      "text": "Missing.",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "Treatment status",
      "text": "used. used. EQ-as as on- as as follows: Ø Ø +00 00 medicraadet@ide ide 234/Proprietary Proprietary - Only Only • date date • interruption interruption date",
      "start_page": 240,
      "end_page": 241
    },
    {
      "heading": "Time to death",
      "text": "date. date. EQ-as as follows: • date date - date date ≤30 • 31 31 ≤ Death date- PRO assessmentdate ≤90 • 91 91 ≤ Death Date - date date ≤183 • ≥date date - date date ≥date date -PRO assessment date≥missing missing (i.e. censored) and",
      "start_page": 241,
      "end_page": 241
    },
    {
      "heading": "Advertise events - Anemia",
      "text": "EQ-of of EQ-5-several, several, mild/as as follows: • Severe: event event (emergent or about) assessment assessment • Mild/moderate: events events (empergent or ongoing) an an .EQ-5L assessment ● Absent: incident incident (extragent or only) an an eq-5D/5L assessment",
      "start_page": 241,
      "end_page": 241
    },
    {
      "heading": "Statistical methodology",
      "text": "the the EQ-index index (dimensions dimensions complete) measures measures (MMRMs): subsequent subsequent EQ/0. 0.",
      "start_page": 241,
      "end_page": 242
    },
    {
      "heading": "descriptive descriptive statistics",
      "text": "for for EQ-Follow-Up Follow-Up (complete complete assessment). box box plots(141) missing missing EQ-5-analyses. analyses.",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "baseline baseline MMRM",
      "text": "visit visit (categorical) effect effect (repeated by subject). squares squares (LS) and and 95% confidence intervals (CIs) presented. presented.",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "values values MMRM",
      "text": "random. random.(143), studies. studies.(143, 144) visit visit (and and follow-up) matrix. matrix.",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "Subject population",
      "text": "the the EQ-5-values values (see main body). Ø Ø +00 00 medikraadet@ide ide 236/23/Proprietary Proprietary - subsequent subsequent EQ/MMRMs. MMRMs.",
      "start_page": 242,
      "end_page": 243
    },
    {
      "heading": "Completion rates",
      "text": "the the EQ-70. 70.97% below below 50% least least 70% 23. 23.",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "Table 69. EQ-time time points",
      "text": "40 mg/17. 17.74% 73.33% 18. 18.55% 79.31% 29. 29.84% 75.51% 25. 25.81% 72.73% 7. 7.4% 73.37% 18. 18.51% 79.32% 14. 14.52% 78.26% 25. 25.13%",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "heading heading <DBS, SNI>",
      "text": "Row 1: in in #28.09.2022; Row 2: •Medical Council • Row 3: Provider • Average Row 4: • Medicinal product • Lumykras (sotorasib) Row 5: Requested indication • with with __MEDTERM0_-mutation",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading <DBS, SNI>",
      "text": "Row 1: • Row 2: False/Strengthening • AIP·Currently negotiated • Row Row 3: • SAIP~Row Row 4: ■ Row 5: • Lumykras •120 mg/stk^240 stk. •13 13 • 13 13 •XXxxX",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading <DBS, SNI>",
      "text": "Row 1: Row 2: XX",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading <DBS, SNI>",
      "text": "Row 1: XXXXXxxXXX_XX XX",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading <DBS, SNI> (from previous page)",
      "text": "Row 1: epi epi 2: XX29/XX ECRXX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (from previous page)",
      "text": "Row 1: • Row 2: Pick up/dosing • Packing price • Number of packs/year • Row Row 3: •SAIP· Row 4: ■ Row 5: Lumykras (sotorasib) •120 mg/stk. •XXxxXXX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (from previous page)",
      "text": "Row 1: Row Row 2: packs/year",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (from previous page)",
      "text": "Row 1: Lumykras Row 2: (sotorasib)",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (column column 1)",
      "text": "Row 1: Row Row 2: Row Row 3: XXRXX XXRXX orXX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (column column 1)",
      "text": "Row 1: • Row 2: Pick up/dosing • Row Row 3: ▪ Row 4: Lumykras (sotorasib) • 120 mg/tk•240 stk.• Row 5: • single single • Row 6: day-to-day (8° Row 7: tk) ■ Row 8: Docetaxel (Kabi) ~ 80 mg/75 75 mg/days days •",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (column column 2)",
      "text": "Row 1: XXX Row 2: Row Row 3: XXxxXXxx Row 4: XX_XX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (column column 2)",
      "text": "Row 1: • Row 2: • Row Row 3: • SAIP Row 4: • Row 5: • XX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (column column 3)",
      "text": "Row 1: XXXX Row 2: XXXX Row 3: XXxx Row 4: XXX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (column column 3)",
      "text": "Row 1: • Row 2: • An paknin·An Row 3: • Paknin-Row 4: ■ Row 5: ~ Row 6: X^12; •",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (column column 4)",
      "text": "Row 1: XX Row 2: XX Raw 3: XX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (column column 4)",
      "text": "Row 1: Row 2: Ntal Row 3: reg/y Row 4: Row 5: Row 6: Row 7: ,18 Row 8:",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (column column 5)",
      "text": "Row 1: XXX Row 2: XXXX Row 3: XXxxXXx",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (column column 5)",
      "text": "Row 1: • Row 2: • Row Row 3: year • Raw 4: • Row Row 5: ■ Row 6: •XX~",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (column column 6)",
      "text": "Row 1: Row 2: meanp Row 3: Row Row 4: Row 5: Row 6: Row 7: XX Row 8: Row 9:",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <DBS, SNI> (column column 7)",
      "text": "Row 1: Row 2: Price Row 3: Row 4: X",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <Amgen Amgen Denmark>",
      "text": "Row 1: Contact information • Row 2: Name • Nicholas Sroczynski",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading <Amgen Amgen Denmark>",
      "text": "Row 1: Jannick Burmester",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading <Amgen Amgen Denmark> (column 1)",
      "text": "Row 1: Row Row 2:",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading <Amgen Amgen Denmark> (column 2)",
      "text": "Row 1: ▪ Row 2: Nicholas Sroczynski",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading <Amgen Amgen Denmark> (column 2)",
      "text": "Row 1: Jannick Burmester",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading < units, and concentrations> (from previous page)",
      "text": "Row 1: Abbreviation term·Definition",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heading heading < units, and concentrations> (column column 8)",
      "text": "Row 1: • Define",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heading heading <5 5 Epidemiology>",
      "text": "Row 1: Baseline characteristics...Danish Row 2: __KRAS G12CRow 3: •patients",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "heading heading <5 5 Epidemiology>",
      "text": "Row 1: Analysis Set...N°event. event.. ..Median OS, Months^6-month __medterm0_,..................Row Row 2: •95% CI) •% (95% CI) =% (95%CI) Row 3: ·",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "heading heading <5 5 Epidemiology>",
      "text": "Row 1: Analysis Set...N°event. event.. ..Median OS, Months^6-month __medterm0_,..................Row Row 2: •95% CI) •% (95% CI) =% (95%CI) Row 3: ·",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "heading heading <5 5 Epidemiology>",
      "text": "two. two...",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "heading heading <treatment treatment options>",
      "text": "Row 1: Year-to-date 2022°2023°2024°2025°2026",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "heading heading <treatment:>",
      "text": "Row 1: Subject·Description",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "heading heading <other other medications>",
      "text": "Row 1: Subject·Description",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading <and and safety>",
      "text": "Row 1: Reference: Row Row 2: (journal, journal, year)",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "100 100 results",
      "text": "Row 1: \"N·mOS Row 2: Patient subgroups• Row 3: \"(_OS_) '\"months (95% CI) Row 4: \"",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "100 100 results",
      "text": "Row 1: Outcome-Study arm...N..Result-Reference.",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "SELECT-1 SELECT-1 results",
      "text": "Row 1: •Outcome •Student arm •N·Result (IQR) •References •",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "heading heading <MAIC MAIC overview>",
      "text": "Row 1: Element...Sotorasib (CodeBreak 100)..Docetaxel (SELECT-1) Row 2: Blinding...\"Open label..Double-blinded Row 3: Inclusion criteria.. ..patients patients (> 18 years) patients patients (>18 years)",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "heading heading <Population Population characteristics>",
      "text": "Row 1: Row Row 2: Received Received > drug drug regiment",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "heading heading <MAIC MAIC approach>",
      "text": "Row-right- right-way- right stock- holder-right, right- right square- right stone- right. right.N= 256 Row 2: Age (mean) Row Row 3: Gender (% feale) Gender#43% Row 4: Brain metastases (%) +21% /NRb Row 5: ECOG (% PS 1 [vs PS 0]) ] •70% ♫59% Row 6: Race (% white) ^82%Row Row 7: % KRAS-G12C+100% .42% Row 8: Anti-PD-(L) line line lines)",
      "start_page": 44,
      "end_page": 44
    },
    {
      "heading": "heading heading <Category Covariate>",
      "text": "RowRowway RowRowway 1: Category ♪Covariate Row 2: ECOG ECOG (0, 1) * Row 3:metastases metastases (Y, N) Row 4: #baseline baseline (Y; N) * Row 5: •expression expression (<5%, >5%) Row 6: following following mutations/alterations: ROS-1 ROS-1 (Y), N) Now 7: Sonewhat importerAge * Row 8: Smoking status (of of smoking) * Raw 9: Row 9:",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "heading heading <Category Covariate> (column 1)",
      "text": "Row 1: Category Row 2: Row Row 3: Row Row 4: other other MAIC",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "heading heading <MAIC MAIC Results>",
      "text": "Row 1: Covariates...important important (Set1) •variables variables (Set2) Row 2: ECOG (% PS 1 [vs PS 0]) •X • X Row 3: Age (mean) ~X Row 4: baseline baseline (% IIIB [ivs IV]) ■X ~ Row 5: Smoking status (% ever smoker) \\X ^X Row 6: level level }X Row 7: Gender (% female) ♫X Row 8: Histology (% Non-squamous) ►X Row 9: Race (% white) /*X Row 10: Key: Oncology Oncology Group; status. status.",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "heading heading <MAIC MAIC Results>",
      "text": "Row 1: X°X",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "heading heading <MAIC MAIC Results>",
      "text": "Row 1: Row Row 2: CovariatesSELECT-1•CodeBreak 100·CodeBreak 100-Row 3: Age (mean) Row Row 4: ECOG (% PS 1 [vs PS 0]) 59% · 70% · 59% Row 5: baseline baseline (% IIIB (vs IV]) 96% *96% •96% Row 6: Smoking status (% ever smoker) 92% b^92% Row 7: Key: Oncology Oncology Group; PD-(L1), death-ligand death-ligand 1; status. status. Note: 2 2 percent",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1: XX Row 2: X A B",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1: XX Row 2: A B",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1: X° X° x° X' X'X' X",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading <adverse adverse events>",
      "text": "Row 1: X· X* X * X * Row 2: X^ X * x * Row 3: X ■ X * ~ X ~ ~",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "heading heading <adverse adverse events> (from previous page)",
      "text": "Row 1: Treatment n (%) • treatment treatment •References",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading <adverse adverse events> (from previous page)",
      "text": "Row 1: Advertise events... Sotorasib (CodeBreak-100)*·Docetaxel + placebo (SELECT-1)** Row 2:",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 1)",
      "text": "Row 1: Treatment N",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 1)",
      "text": "Row 1: Row Row 2:",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 2)",
      "text": "Row 1: •n (%) •",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 2)",
      "text": "Row 1: Sotorasib (CodeBreak-100)*·Docetaxel + placebo (SELECT-1)** Row 2:",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "Table 19.",
      "text": "Row 1: Patient population...Clinical documentation /•model. model.. ..Row Row 2: \"etc. etc...\" \"Including source\" Row 3: Important baseline \"Row 4: characteristics·",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "Table 21. Comparator",
      "text": "Row 1: Intervention·Clinical documentation·model model \"Row Row 2: \"(including source') '; (number/practice practice (Row Row 3: \" Row 4: 'source) '; 'if known) Row 5: \"",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "Table 21. Comparator",
      "text": "Row 1: model. model...Row Row 2: •(including source) • (number/value including • practice (including source) Row 3: • Row 4: •source) ■ Row 5: ▪",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "Table 22.",
      "text": "Row 1: outcome outcome Sotorasiba·Docetaxelb",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <A B>",
      "text": "Row 1: X • Row 2: X ~X ~ X ■ Row 3: X ^X \\X __X } ~ Row 4: X ·X • X £X − Row 5: ~x ~ x ~ ~ * X ► Row 6: Key: CI, confidence interval; sample sample size; HR, hazard ratio; indirect indirect comparison; mth, months; OS, overall survival; ~MEDTERM1___, progression-freevival.",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "heading heading <A B>",
      "text": "Row 1: XX Row 2: A B",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "heading heading <Statistical goodness-of-fit>",
      "text": "2 2 ................8 8 •8 8 !Row Row 4: Gompertz",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "heading heading <XX>",
      "text": "Row 1: XX • Row 2: •Exp • Gompertz • Weibull •GG • Log-logistic •Log-normal Row 3: Sotorasib • Raw 4: 2 months • 91.3% •91.0% • 92.9% • 95.8% •94.7% •95.5% Row 5: 6 months ~76.0% *75.6% •77.7% ■76.9% −78.0%",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "heading heading <5-years 5-years (10-years 10-years (rate, rate, duration>",
      "text": "Row 1: Doceteknavel • Row 2: 2 months • 85.8% •85.5% • 88.3% •89.1% • 89.2% • 79.3% Row 3: 6 months ~63.3% ~62.7% ~65.5% ~60.7% • 62.0% • 61.6% Row 4: 12 months ■ 40.0% *39.9% • 39.9% ~38.2% ~37.0% / 38.1% Row 5: Key: Exp, exponential; GG, Generalized gamma; survival. survival.",
      "start_page": 62,
      "end_page": 62
    },
    {
      "heading": "heading heading <5-years 5-years (10-years 10-years (rate, rate, duration>",
      "text": "Row 1: XX",
      "start_page": 62,
      "end_page": 62
    },
    {
      "heading": "heading heading <Statistical goodness-of-fit>",
      "text": "Row 1: XX Row 2: A B",
      "start_page": 63,
      "end_page": 63
    },
    {
      "heading": "heading heading < Statistical goodness-of-fit> (from previous page)",
      "text": "Indepenent fit • fit fit (restricted)Joint fit (stricted),Joint fit (rested)Row 2:",
      "start_page": 64,
      "end_page": 64
    },
    {
      "heading": "heading heading <curve curve selection>",
      "text": "Row 1:",
      "start_page": 67,
      "end_page": 67
    },
    {
      "heading": "the the Denmark",
      "text": "Row 1: XX",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "the the Denmark",
      "text": "Row 1: XX°-Row 2: X°-X°-x°-ax-X'-X-X",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "heading heading <mode mode discipline>",
      "text": "Row 1: XX°-Row 2: X°-X°-x°-ax-X'-X-X",
      "start_page": 73,
      "end_page": 73
    },
    {
      "heading": "heading heading <mode mode discipline>",
      "text": "Row 1: X· X* X* x* X * X*",
      "start_page": 73,
      "end_page": 73
    },
    {
      "heading": "heading heading <mode mode discipline>",
      "text": "Row 1: X· X* X* x* X * X*",
      "start_page": 73,
      "end_page": 73
    },
    {
      "heading": "heading heading <resource resource use>",
      "text": "Row 1: Advertise event...Mean (95% CI)*..Source Row 2:",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "heading heading <management management costs>",
      "text": "Row 1:Unit·Unit *Reference *apply apply *Row Row 2: •[DKK) •dose •month Row 3: • Row 4: •intensity •(DKK]d Row 5: •",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "heading heading <management management costs>",
      "text": "Row 1: Drug...Cost (DKK)•Source",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "heading heading <management management costs>",
      "text": "Row 1: • Row 2: • Unit cost • Raw 3: Blood sample • Source Row 4: • R. R. 5: • Roll 6: ■",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "Table 29.",
      "text": "Row 1: • Row 2: Units • unit unit (DKK) • Source Row 3: •",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "Table 29.",
      "text": "Row 1: • Row 2: • Health states • Raw 3: ■ Row 4: • First cycle • Progression-free • Row 5: Units • Accountance-free• Subsequential cycles • Post-progress Row 6: ● Frequency per cycle) •(frequency per cycle), • défrequency per bicycle)",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "heading heading <transport transport cost>",
      "text": "Row 1: • Row 2: Advertise event • Cost (DKK) • Source a",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "heading heading <transport transport cost>",
      "text": "Row 1: •Unit cost • Row 2: Resource •Source Row 3: •(DKK) •",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "heading heading <importance· (SET 1) samples size.>",
      "text": "Row 1: \"Time usage\" Row 2: \"Resource\"\"Source Row 3: \"(mins.) \"",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "heading heading <importance· (SET 1) samples size.>",
      "text": "Row 1: Category...Base-case analysis.. ..Rational",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "heading heading <sensitivity sensitivity analyses>",
      "text": "Row 1: XX°-- Row 2:-- -- Row 3:-- X°-X°-x°-",
      "start_page": 80,
      "end_page": 80
    },
    {
      "heading": "heading heading <Scenario Scenario analysis>",
      "text": "Row 1: No. •Scenario •Base-case Assumption • Rationale",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "heading heading <Scenario Scenario analysis> (column 1)",
      "text": "Row 1: No. •Scenario •Base-case Assumption •",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "heading heading <Scenario Scenario analysis> (column 2)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "heading heading <Scenario Scenario analysis> (column 3)",
      "text": "Row 1: • Rationale",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1: XX°-Row 2: X°-X°-x-X-X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1: X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1: X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1: X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1:",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1:",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1: X· X* X* x* X * X*",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1: X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1: X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1: X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1: X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1:",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading <XXX XX>",
      "text": "Row 1:",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading <found. found.), a a X% the the DKK>",
      "text": "Row 1: XX°-Row 2: X°-X°-x°-Z-X-X'-Row 3:",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "heading heading <Scenario Scenario analysis>",
      "text": "Row 1: • Year 1· Year 2· Year 3· Year 4· Row Row 2: ■",
      "start_page": 86,
      "end_page": 86
    },
    {
      "heading": "heading heading <Scenario Scenario analysis>",
      "text": "Row 1: • Year 1· Year 2· Year 3· Year 4· Row Row 2: ■",
      "start_page": 86,
      "end_page": 86
    },
    {
      "heading": "heading heading <Scenario Scenario analysis>",
      "text": "Row 1: X° Row 2: ... X° X°X° X* X°",
      "start_page": 86,
      "end_page": 86
    },
    {
      "heading": "heading heading <monotherapy monotherapy (X]), in in median>",
      "text": "Row 1: XX°-Row 2: X°-X°-x-X-X",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "heading heading <monotherapy monotherapy (X]), in in median>",
      "text": "Row 1: XX°-Row 2: X°-X°-x-X-X",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "heading heading < Conclusion> (from previous page)",
      "text": "Row 1: • Xxxxrow 2: • xxxxxdexxxxx",
      "start_page": 90,
      "end_page": 90
    },
    {
      "heading": "heading heading <Conclusion> (column column 1)",
      "text": "Row 1: • Xxxxx Row 2: • xxxxx",
      "start_page": 90,
      "end_page": 90
    },
    {
      "heading": "heading heading <Conclusion> (column column 2)",
      "text": "Row 1: xxx Row 2: xxx",
      "start_page": 90,
      "end_page": 90
    },
    {
      "heading": "heading heading < Conclusion> (column column 3)",
      "text": "Row 1: xxx Row 2: xxxxx",
      "start_page": 90,
      "end_page": 90
    },
    {
      "heading": "heading heading <Conclusion> (column column 4)",
      "text": "Row 1: xx Row 2: xx",
      "start_page": 90,
      "end_page": 90
    },
    {
      "heading": "heading heading < Embase • original search>",
      "text": "Row1Right Row1Right 1: \"Searches' means 11: Row 2: 1;lung lung cancer/=9821 Row 3: 2 lairlung cancer/ ab. ab.•14730 Row 4: 3·_nsclc_.ti-,Row Row 5: Row Row 6: 5*carcinom$ or cancer$ or neoplas$).ti,ab.",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "heading heading < Embase • original search> (column 1)",
      "text": "Row 1: Row 2: 1 Row 3: 2 Row 4: 3 Row 5: 4 Row 6: 5 Row 7: 6 Row 8: 7 Row 9: 8 Row 10: 9 Row 11: 10 Row 12: 11 Row 13: 12 Row 14: 13 Row 15: 14 Row 16: 15 Row 17: 16 Row 18: 17 Row 19: 18",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "heading heading < Embase • original search> (column 9)",
      "text": "Row 1: Results Row 2: 98821 Row 3: 14730 Row 4: 81646 Row 5: 102425 Row 6: 3177270 Row 7: 933416 Row 8: 156582 Row 9: 690342 Row 10: 2272961 Row 11: 2372831 Row 12: 4395903 Row 13: 2158432 Row 14: 16155 Row 15: 6524 Row 16: 9631 Row 17: 2485 Row 18: 3950 Row 19: 6435",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "heading heading < Embase original search> (from previous page)",
      "text": "Row$1 ====&gt;== &gt;&lt;= &lt; ==& #&gt: $13\"R77$1:==#Searches•Results Row 2:1 ^lung lung cancer/=52621 Row 3:2·lung cancer/ ab. ab.",
      "start_page": 100,
      "end_page": 100
    },
    {
      "heading": "heading heading < Embase original search> (column column 1)",
      "text": "Row 1: # Row 2: 1 Row 3: 2 Row 4: 3 Row 5: 4 Row 6: 5 Row 7: 6 Row 8: 7 Row 9: 8 Row 10: 9 Row 11: 10 Row 12: 11 Row 13: 12 Row 14: 13 Row 15: 14",
      "start_page": 100,
      "end_page": 100
    },
    {
      "heading": "heading heading < Embase original search> (from previous page)",
      "text": "to to 1: # hoseSearches -Results Row 2: 1;lung lung cancer/Row Row 3: 2;lung cancer/ ti, ti,ab: 3559 Row 4: 3___nsclc.ti-,ab.",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "heading heading < Embase original search> (column column 1)",
      "text": "Row 1: # Row 2: 1 Row 3: 2 Row 4: 3 Row 5: 4 Row 6: 5 Row 7: 6 Row 8: 7 Row 9: 8 Row 10: 9 Row 11: 10 Row 12: 11 Row 13: 12 Row 14: 13 Row 15: 14 Row 16: 15 Row 17: 16 Row 18: 17 Row 19: 18",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "heading heading < Embase original search> (column column 6)",
      "text": "Row 1: Results Row 2: 4213 Row 3: 3559 Row 4: 9389 Row 5: 11599 Row 6: 169791 Row 7: 51312 Row 8: 13703 Row 9: 137 Row 10: 1118684 Row 11: 1118699 Row 12: 2072 Row 13: 1117419 Row 14: 9466 Row 15: 4281 Row 16: 4213 Row 17: 3559 Raw 18: 9389 row 19: 115999",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "heading heading < Embase - 2021 update>",
      "text": "Row 1: 19°8312 Row 3: 21°or or (and and 20) 13703 Row 4: 22°crossover procedure/ or double-blind procedure/controlled controlled trial/or single-blind proceeding/.137 Row 5: 23°(random$or facto$or crossover$or Cross-over$ or placebo$or (doubl$adj blind$) or (singl$dj blind $) or assign$or allocat$or volunteer$).ti,ab.",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "heading heading < Embase - 2021 update>",
      "text": "Row 1: •Searches •Results Row 2: 1 •lung lung cancer/ •105188 Row 3: 2 •lung cancer/ ab. ab. *14842 Row 4: 3 •__MEDTERM0_.ti;ab. •85349 Row 5: 4 •4 4 •106532 Row 6: 5 •(carcinom$ or cancer$ or neoplas$).ti,ab. ■3202195 Row 7: 6 •lung$.ti.ab. +930054 Row 8: 7 •or or (and and 6) •163414 Row 9: 8 •crossover procedure/ or double-blind procedure/controlled controlled trial/or single- blind procedure/·708522",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "heading heading <Embase - 2021 update> (column 1)",
      "text": "Row 1: 19 Row 2: 20 Row 3: 21 Row 4: 22 Row 5: 23 Row 6: 24 Row 7: 25 Row 8: 26 Row 9: 27 Row 10: 28",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "heading heading <Embase - 2021 update> (column 1)",
      "text": "Row 1: Row 2: 1 Row 3: 2 Row 4: 3 Row 5: 4 Row 6: 5 Row 7: 6 Row 8: 7 Row 9: 8",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "heading heading <Embase - 2021 update> (column 6)",
      "text": "Row 1: 169791 Row 2: 51312 Row 3: 13703 Row 4: 137 Row 5: 1118684 Row 6: 1118699 Row 7: 2072 Row 8: 1117419 Row 9: 9466 Row 10: 4281",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "heading heading <Embase - 2021 update> (column 6)",
      "text": "Row 1: Results Row 2: 105188 Row 3: 14842 Row 4: 85349 Row 5: 106532 Row 6: 3202195 Row 7: 930054 Row 8: 163414 Row 9: 708522",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "heading heading < Embase - 2021 update> (from previous page)",
      "text": "orrandom$or facto$or crossover$orcross over$or Cross-over$ or placebo$or (doubl$adj blind$)or (singl$dj blind $)or assign$or allocat$or volunteer$).ti,ab.",
      "start_page": 103,
      "end_page": 103
    },
    {
      "heading": "heading heading <Embase - 2021 update> (column column 1)",
      "text": "Row 1: 9 Row 2: 10 Row 3: 11 Row 4: 12 Row 5: 13 Row 6: 14 Row 7: 15 Row 8: 16 Row 9: 17 Row 10: 18 Row 11: 19 Row 12: 20 Row 13: 21 Row 14: 22",
      "start_page": 103,
      "end_page": 103
    },
    {
      "heading": "heading heading <Embase - 2021 update> (column column 8)",
      "text": "Row 1: 2312465 Row 2: 2412281 Row 3: 4232620 Row 4: 2193742 Row 5: 16797 Row 6: 6842 Row 7: 9955 Row 8: 2796 Row 9: 4278 Row 10: 7074 Row 11: 230158 Row 12: 383 Row 13: 265 Row 14: 505",
      "start_page": 103,
      "end_page": 103
    },
    {
      "heading": "heading heading < Embase - 2021 update> (from previous page)",
      "text": "Row$*555228 Row 3: 2 ~lung cancer/ ab. ab.",
      "start_page": 104,
      "end_page": 104
    },
    {
      "heading": "heading heading <Embase - 2021 update> (column column 1)",
      "text": "Row 1: # Row 2: 1 Row 3: 2 Row 4: 3 Row 5: 4 Row 6: 5 Row 7: 6 Row 8: 7 Row 9: 8 Row 10: 9 Row 11: 10 Row 12: 11 Row 13: 12 Row 14: 13 Row 15: 14 Row 16: 15 Row 17: 16 Row 18: 17",
      "start_page": 104,
      "end_page": 104
    },
    {
      "heading": "heading heading < Embase - 2021 update> (from previous page)",
      "text": "Row=10$299-or placebo (single-blind single-blind procedure/ •137 Row 10: 9;14278 Row 9: 8; crossover procedure/ or double-blind process/controlled controlled trial/or single- blind procedure/",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "heading heading <Embase - 2021 update> (column column 1)",
      "text": "Row 1: # Row 2: 1 Row 3: 2 Row 4: 3 Row 5: 4 Row 6: 5 Row 7: 6 Row 8: 7 Row 9: 8 Row 10: 9 Row 11: 10 Row 12: 11 Row 13: 12 Row 14: 13 Row 15: 14",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "heading heading <Embase - 2021 update> (column column 2)",
      "text": "Row 1: Results Row 2: 4365 Row 3: 3663 Row 4: 9820 Row 5: 12057 Row 6: 178044 Row 7: 54134 Row 8: 14278 Row 9: 137 Row 10: 1178914 Row 11: 1178829 Row 12: 2106 Row 13: 1177616 Row 14: 9948 Row 15: 517",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "heading heading < ras ras oncogene/ 9909>",
      "text": "Row 1: #hSearches;Results Row 2: 2: 1·cell cell cancer/",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "heading heading < ras ras oncogene/ 9909> (from previous page)",
      "text": "7: 30 30 (6) 660 Row 8: epi epi epidemiology/or epidemic $or or V-Kirsten Kirsten RAS) adj5Row 3: • Row 4: ~mutation$ or mutant$ or or gene$ or decoration$ Or Or RASK$ or or RUS) adj5 , or oncoke$ or fusion$ or oncegen$ or merger$ or expression$ or over .expression$ Row Row 6:",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "heading heading < ras ras oncogene/ 9909> (column column 1)",
      "text": "Twenty-seven-six-size-two-twenty-three-show-two.Row-one-five-zero-four-two, Row-tw-twe-twer.Rown-tWrow-tah-tlf.ROW-Two-twice-one.Raw-Tw-Tho-Twe-Twi-Thr-Tright-Tree-Turk-Tri-Trip-Tax.Trow_twj-tv-Row Row 3: •Row 4: ^mutation$ or mutant$ Row Row 5: or oncogene$ or Row 6: or inversion$ Row Row 7: 12°Row Row 8: 13° epidemiology/ Row Row 11: 16·overall survival/or (Row Row 12: ~prolong*orvival* or survival.: 22.ti.",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "heading heading < ras ras oncogene/ 9909> (column column 2)",
      "text": "Row 1: -K-ras or V-or or c-Row Row 2: Row Row 3: or or gene$ Row Row 4: fusion$ or expression$ or over?expr Row 5: n$)).Row Row 6: Row 7: w. Row 8: Row 9: Row 10: urvival* term term survival* Row Row 11: Row Row 12: Row Row 13: Row 14: nse or TTR).mp. Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "heading heading < ras ras oncogene/ 9909> (column column 3)",
      "text": "Row 1: c-k-ras Row 2: Row Row 3: oratio Row 4: ressio Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: surviv Row 11: Row 12: al).Row Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "heading heading < ras ras oncogene/ 9909> (column column 4)",
      "text": "Row 1: s or ki-•Row Row 2: S) adj5",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293>",
      "text": "Row 1: 31°to to (or or \"review\" or short",
      "start_page": 109,
      "end_page": 109
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293>",
      "text": "1 1 0Row=Row Row 2: 1-exp Carcinoma, Non-Small-Cell Lung/ an an anus) Rsulps Row: 1-aspexp Carcinoma, Non-Small-Cowl-Cel-Cow-Chow-Cown cancer).Ti,ab.",
      "start_page": 109,
      "end_page": 109
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (from previous page)",
      "text": "right right right- right right right/Row Row 4: 15pevalence/or survival.ti;kwowowwoww!Row 7: 'Row 8: 17jæsenon free survival* or overall survival* Or •Row Row 6: •prolong$ survival* and survival*or survival anal$).Sourvaval Sourvaval Analysis/or (disease specific survival* of sleep* or above again* orover* or survive* or survival*) or survival Anal$'. or survival' or survivalanal$ 7 7 7:",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (column column 1)",
      "text": "Row 1: 20/22 and 17: Rowis Rowis 15: 24.",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (column column 2)",
      "text": "Row 1: Row 2: ,Row Row 3: Row 4: w. Row 5: Row Row 6: l$).Row Row 7: Gressio Row 8: p. Row 9:espon Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row Row 23: \".mp.",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (column column 3)",
      "text": "Row 1: Row 2: w. Row 3: Row 4: Row 5: Urvival* Row Row 6: Row Row 7: Row Row 8: Row 9: nse or TTR).mp. Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: view (topic)\"/ Row Row 23: or meta-analysis.mp",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (column column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: Row 7: Ores Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Ystem Row 23: p.",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (column column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: vival* Row 6: Row 7: ssion-f Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: matic Row 23:",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (column column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: Row 7: Row Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Revie Row 23:",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (column column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Verall Row 6: Row 7: Surviva Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row Row 23:",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (column column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Surviv Row 6: Row 7: al).Row Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row Row 23:",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (column column 9)",
      "text": "Row 1: ..Row Row 2: ..Row Row 3: •Row Row 4: •Row Row 5: val* or •Row Row 6: • Row 7: ■ Row 8: ab,kw. •Row Row 9:",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (from previous page)",
      "text": "Row 1: 33·31 not 32·131 Row 2: 34·30 not 33·1430 Row 3: 35·from from 34·1427",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (from previous page)",
      "text": "5j3 5j3 (Marque$ square square right) adJ3 (wwright) adj3: 1-expRccinoma, Non-Small-Cell Lung/=ceO3982 ororororrororwise 3: 2·lung lung cancer).ti,ab.•Row Row 4: Row Row 5: to to yr=\"2014 -Current\" [in in DARE; records were established]5674 or rectum$ or colon$ or sigma$ or segmo$ or rectosigm$ or sign$ or sell cancer/ or suggest cancer/or brain cancer/Or colectal tumor/Row Row 7: 6",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (column column 1)",
      "text": "Row 1: 33 • Row Row 2: 34 • Row Row 3: 35 • from from 34",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (column column 1)",
      "text": "US US 1*exp Carcinoma, Non-Small-Cell Lung/oRow: 2°lung lung cancer).ti,ab.",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (column column 2)",
      "text": "Row 1: •131 Row 2: • 1430 Row 3: •1427",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12 293> (column column 2)",
      "text": "Row 1: ..5674 Row 6: ..7717 Row 7: owel$or•Row Row 8: cinoma$°Row 9: . ..ti,ab.-Row 10: ·Row Row 11: ^Row Row 12: ■Row Row 13: ~65 Row 14: ras or ki-*1176 Row 15: AS) adj5",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "heading heading < • Embase ~ updated search: 10 March 2021>",
      "text": "Row 1: 24 • Letter / • 0 Row 2: 25 •or/22-24 • 2133 Row 3: 26 •25 25 ■Row Row 4: 27 • 26 26 ■ 651 Row 5: 28 •(animal$ not human$).sh,hw. • 2033 Row 6: 29 •28 28 ~651 Row 7: 30 •language language [DARE, DARE,CLCMR; records521 Row 8:",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading < • Embase ~ updated search: 10 March 2021>",
      "text": "Row 1: #=Searches;Results Row 2: 2: 1·cell cell cancer/",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading < • Embase ~ updated search: 10 March 2021> (column 1)",
      "text": "Row 1: 24° Letter/ Row 2: 25°or/22-24 Row 3: 26°Row Row 4: 27°Row Row 5: 28°(animal$ not human$).Row Row 6: 29°Row Row 7: 30°language language [Row Row 8:",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading < • Embase ~ updated search: 10 March 2021> (column 1)",
      "text": "Row 1: #·Searches Row 2: 1 •cell cell cancer/",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading < • Embase ~ updated search: 10 March 2021> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row Row 8: Row 9: Row Row 10: Row 11: Row Row 12: Row 13: Row 14: Row 15:",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading < • Embase ~ updated search: 10 March 2021> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: $ Row Row 8: n$ Row Row 9: adenom$o Row 10: Row 11: Row 12: Row 13:",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading < • Embase ~ updated search: 10 March 2021> (column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: RE,CLCMR; reco Row 8: Row 9: Row Row 10: Row 11: Row Row 12: Row 13: Row 14: Row 15:",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading < • Embase ~ updated search: 10 March 2021> (column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: sigm$ or bowl$ Row 8: o?r$ Row Row 9: or lesion$)).Row Row 10: Row 11: Row 12: Row 13:",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading < • Embase ~ updated search: 10 March 2021> (column 4)",
      "text": "Row 1: \"0 Row 2: \"2133 Row 3: \"Row Row 4: \" 651 Row 5: \"2033 Row 6: \"651 Row 7: words \"521 Row 8: \" Row 9: \" Row Row 10: \" ' Row 11: \"Row Row 12: \" Bow 13: '0 Row 14: \" 521 Row 15: '507",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading < • Embase ~ updated search: 10 March 2021> (column 4)",
      "text": "Row 1: \"Results Row 2: \"106879 Row 3: \"116340 Row 4: \"160606 Row 5: \"34076 Row 6: \"339744 Row 7: $ or \"367191 Row 8: \" Row 9: ' Row 10: ' b. ' Row 11: '442830 Row 12: '62540 Row 13: '94311 Row 14: '11065",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading < • Embase updated search: 10 March 2021> (from previous page)",
      "text": "7: 11 11 .35639 Row 8: 13 • epi epi epidemiology/or overexpression$ orright$ or mutant$ ormuted or reputation$ Kirsten Kirsten RAS) adj5Row 3:",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "heading heading < • Embase updated search: 10 March 2021> (column column 1)",
      "text": "RowRowway 1 1: 11 ('or or V-Ki- stock$ or W-or or c-ROW ROW 3: • Row 4: ^mutation$ or mutant$ or or gene$ Row Row 5: •rearrangement$ or oncogene$ or fusion$ or or expression$ or over ?exp Row 6: ................amplification$ or inversion$ or division$)).Row Row 7: Row Row 8: 13.7. epidemiology/Row Row 9: 14",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "heading heading < • Embase updated search: 10 March 2021> (column column 2)",
      "text": "Row 1: c-k-ra Row 2: Row Row 3: oratio Row 4: ressio Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: survi Row 11: Row 12: val).ti, Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "heading heading < • Embase updated search: 10 March 2021> (column column 3)",
      "text": "Row 1: as or ki-",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "heading heading <ras ras oncogene/ 12466>",
      "text": "Row 1: 31°to to (or or \"review\" or short",
      "start_page": 114,
      "end_page": 114
    },
    {
      "heading": "heading heading <ras ras oncogene/ 12466>",
      "text": "Row2 RowRaw 1: #=Searches-Rough-Results Row 2: Carcinoma, Carcinoma, Non-Small-Cell Lung/ ororOrororrororway ororOrororrororway 3: 2·lung lung cancer).Ti,ab.n-Small-Cowl-Cill-to to yr=\"2019 -Current'-151554 Row 6: 5",
      "start_page": 114,
      "end_page": 114
    },
    {
      "heading": "heading heading <ras ras oncogene/ 12466> (from previous page)",
      "text": "rightwaywayright rightwaywayright right-arrowing/Survival Survival Analysis/or (disease specific survival* term term survival*all all survival* and/or overall survival* Row Row 6: celong$ survival*Or survival anal$).Row Row 9: 18.Candoverall response: see 8: 17.",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading <ras ras oncogene/ 12466> (column column 1)",
      "text": "Row 1: 12° Row Row 2: 13° epidemicology/ Row Row 3: 14° incidence/ ti ti (disease specific survival* Row Row 6: prolong$ survival*orvival anal$).Row Row 7:",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading <ras ras oncogene/ 12466> (column column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: Row 7: Row Row 8: Row 9: mp. Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: )\"/ Row Row 23: alysis.mp.",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading <ras ras oncogene/ 12466> (column column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Surviv Row 6: Row 7: Gress Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Stama Row 23:",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading <ras ras oncogene/ 12466> (column column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: val* o Row 6: Row 7:sion-f Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: atic Row 23:",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading <ras ras oncogene/ 12466> (column column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: Row 7: Row Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: review Row 23:",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading <ras ras oncogene/ 12466> (column column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Verall Row 6: Row 7: Surviv Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row Row 23:",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12466> (column column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: survi Row 6: Row 7: val).ti, Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row Row 23:",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading < ras ras oncogene/ 12466> (column column 8)",
      "text": "Row 1: •24918 Row 2: •198048 Row 3: •888464 Row 4: •745199 Row 5: Ival* or •361241 Row 6: •Row 7: ▪ Row 8: ,ab,kw.",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading < • Cochrane updated search: 10 March 2021>",
      "text": "Row 1: 33 • 32 32 • 19 Row 2: 34 • 33 33 ■ 407 Row 3: 35 • 34 34 ~ 407",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "heading heading < • Cochrane updated search: 10 March 2021>",
      "text": "Row2Row square 1: #=Searches;Results Row 2: 1-exp Carcinoma, Non-Small-Cell Lung/",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "heading heading < • Cochrane updated search: 10 March 2021> (column 1)",
      "text": "Row 1: 33 • Row Row 2: 34 • Row Row 3: 35 • from from 34",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "heading heading < • Cochrane updated search: 10 March 2021> (column 1)",
      "text": "square square US-Row-Wow-ough-ROWS ough-ROWS 1#Searches Row 2: 1°exp Carcinoma, Non-Small-Cell Lung/Row 5: 4 /to to yr=\"2019 -Current\" [in in DARE; records were established].Row 6: 5",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "heading heading < • Cochrane updated search: 10 March 2021> (column 2)",
      "text": "Row 1: \"19 Row 2: \"407 Row 3: \" 407",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "heading heading < • Cochrane updated search: 10 March 2021> (column 2)",
      "text": "Row 1: #Results Row 2: #4656 Row 3: #14347 Row 4: #14819 Row 5: #2010 Row 6: #8922 Row 7: #25271 Row 8: #144 Row 9: # Row 10: #10,ab.# Row 11: #26344 Row 12: #3676 Row 13: #5654 Row 14: #66 Row 15: as or ki-",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "heading heading <• Cochrane updated search: 10 March 2021> (from previous page)",
      "text": "holder holder is:RowRightway 1; RowRawright Rive 1: 14.RowStore/ownership, ownership,right-right-of of survival* term term survival*or overall survival* and/Row Row 4: \"prolong$ survival*and survival' or survival anal$).kwew. kwew.:25533 Row 5: • Row 6: free free survival/or (progression-free progression-free survival) or progression -free survival).ti,akwww.................7 7 7: 18 : 18",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "heading heading < • Cochrane updated search: 10 March 2021> (column column 1)",
      "text": "right-right right-right right/ab, ab,kw: Row 2: 15;right right right/ rightway rightway right/Way Way 1: 14;incident/Row Row 5: • Row 6: 17jædeon free survival/or (Row Row 7: or or _ORR_).mp. Row 8: 19.",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "heading heading <• Cochrane updated search: 10 March 2021> (column column 2)",
      "text": "Row 1: Row 2: Row 3: val* Row Row 4: Row 5:Row Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row Row 19: Row 20: Row Row 21: Row 22: Row Row 23: Row 24:",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "heading heading <• Cochrane updated search: 10 March 2021> (column column 3)",
      "text": "Row 1: • 123869 Row 2: • 41883 Row 3: survival* or • 105477 Row 4: • Row 5: ▪ Row 6: val).kw. kw.",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "heading heading <34 34 65>",
      "text": "Row 1: 34°30 not 33°65 Row 2: 35°from from 34°65",
      "start_page": 118,
      "end_page": 118
    },
    {
      "heading": "heading heading <34 34 65>",
      "text": "_ _ __MEDTERM2_right-still-st-stable_ t2_during_right_right (Row_right) Row: Population_Adults (18 years) metastatic metastatic (stage IIIB-IV) separately separately '. limited limited to: • PD-L1 expression • Prior PD- L1 exit • Pre-PD-(L)1 therapies • progressorsonsors progressorsonsors • adolescent adolescent (< 18 years) Patients • Patients with cancer'_BAR _BAR P-ind-and L) 2__ 2__ • Ear-stin-T2_T2 T2_T2 [...] s s S",
      "start_page": 118,
      "end_page": 118
    },
    {
      "heading": "heading heading < Safety and tolerability:>",
      "text": "\"Rowights' 2 2 (1) (a) of Directive 2014/65/Council Council [9];",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "heading heading < Safety and tolerability:> (column 1)",
      "text": "Row 1: Criteria",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "heading heading < Safety and tolerability:> (column 2)",
      "text": "case, case, \"Row-Right- than-right-over-right Row 2: • rate rate (ORR_) • Partial response (PR) ♪ Complete response (CR) ■ rates rates • response response • rate rate • termination termination (etc. etc.) Safety and tolerability: • AEs AEs • 4 4 AEs; • SAEs SAEs ● • Tolerantability: discontination discontination (any reason), discontuation (due to AEs) ] Row 3:",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "heading heading <2) SLR Screen:>",
      "text": "through through 4: NSCLC_ NSCLC_ (Row Row 5: Proceedings) Row Row 6: • Row 7: \"Row 7: 'mutation mutation (KRASm) Row 8: Interventions and 8: treatment treatment or",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading <2) SLR Screen:>",
      "text": "Row 1: Date Row 2: restrictions",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading <2) SLR Screen:> (column 1)",
      "text": "Row 1: \"Eligibili Row 2: \"criteria Row 3: \"Popula Row 4: \"Interve Row 5: \"Compa Row 6: \"Outcom Row 7: Study d· Row Row 8: Date restrictive\" Date Row 9: \"Restrict Row 10: \"Langua Row 11: \"restrict\"",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading <2) SLR Screen:> (column 2)",
      "text": "Row 1: ity Row 2: a Row 3:ation Row 4: Row 5: entry Row 6: Row 7: arator Row 8: mes Row 9: Row 10: design Row 11: Row 12: Row 13:tions Row 14: Row 15: age Row 16: tions",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading <2) SLR Screen:> (column 3)",
      "text": "RowRowway Hoover Criteria:Exclu Row 2: in: Row 3: • Row 3: # Ro 4: #NSCLC_ NSCLC_ (Row Row 5:",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading <2) SLR Screen:> (column 3)",
      "text": "Row 1: Row 2:",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading <2) SLR Screen:> (column 4)",
      "text": "Row 1: Row Row 2: Row 3: Row Row 4: Row 5: Row Row 6: accustomed comparator arm) Row 7: Row 8: Row 9: Row 10: out animal/Row Row 11: Row Row 12: Row 13: Row 14: Row 15: Row 16:",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading <2) SLR Screen:> (column 5)",
      "text": "Row 1: Row 2: Row 3: SCLC Row 4: Row 5: reputation (u Row 6: Row 7: Row 8: Row 9: Row 10: studio Row 11: Row 12: Row 13: Row 14: Row 15: Row 16:",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading <2) SLR Screen:> (column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Unless Row 6: Row 7: Row 8: Row 9: Row 10: Row Row 11: Row 12: Row 13: Row 14: Row 15: Row 16:",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading <2) SLR Screen:> (column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row Row 6: Row 7: Row 8: Row 9: Row 10: case Row 11: Row 12: Row 13: Row 14: Row 15: Row 16:",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading <excluded excluded RCTs>",
      "text": "Row 1: Publication type...and and .. Row 2: systematic systematic reviews*.. ..Row 3: • Row 4: \"Country\"",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "reliability reliability criteria",
      "text": "2 mg/Row Row 2: Row Row 3: 2015 2015 (2011/101) study study (United United States) concluded b ¥ daily daily (n=86) United United states) July July 2012] day day (n = 2 mg / h=86), WITM0 - received received >were were excluded*0 0 , function function 2) medications. medications.",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "reliability reliability criteria",
      "text": "Row 1: Row Row 2: Row Row 3: reason",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "reliability reliability criteria",
      "text": "Row 1: Row Row 2: 2015(101) Row 3: NCT01362296 Row 4: Phase 2",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "reliability reliability criteria",
      "text": "Row 1: NCT01229150; CTEP: 8444 Row 2: Phase 2",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "reliability reliability criteria",
      "text": "Row 1: region region • patients patients •Prior therapy •Inclusion criteria •Exclusion criteria",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "reliability reliability criteria",
      "text": "2015 2015 (101) NCT01362296 Phase 2=International study (United United States) daily daily (n=86) Docetaxel 75 mg/weeks weeks (n=3) (1) advanced advanced stage/metstatic stage __MEDERTM8_____1) Patients aged ≥ ECOG ECOG 2010waywayway",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "reliability reliability criteria",
      "text": "Row 1: Row Row 2: Row 3: Row Row 4: Row Row 5: appropriate appropriate intervention",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "75 75 mg/m2 day (n=51) daily daily (n = 51) Investitor'500 500 mg/ mg mg / 21day 21day (n=3 12 mg/ma2 days (1) 21 21 days;",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: reason",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: NCT02152631 Row 2: Phase 3",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (column column 1)",
      "text": "(21 21 days) (n=45)",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "heading heading <reliability reliability criteria> (column column 3)",
      "text": "Row 1: Row Row 2: Row 3: relevant relevant intervention",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "region region •Row Row 2: January January 2016;__MEDTERMM0___ __MEDTERMM0___ (hydrogen chaine) 2017 2017 (72) Phase Phase 3·2016 2016 2) tumor tumor 3) 1 1 January1) compression compression (for for ≥ to to screening).",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: reason",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: NCT01933932 Row 2: SELECT-1 Row 3: Phase 3",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: 2016 (106) Row 2: BATTLE-2 Row 3: Phase 2",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (column column 1)",
      "text": "Row 1: • Row 2: 3 3 • Row Row 3: • NCT0933932 Row 4: • SELEKT-1 Row 5: • Row Row 6: Papadimitrakop 2016 (106) 2 2 • Papadimitracop Row 7:",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading <reliability reliability criteria> (column column 2)",
      "text": "of of patients;Study Study , Interferences Interferences details; passengersPriory passengersPriory anyway;Row Row 2: •Row Row 3: 7 (72) 'selumetinib selumetinib (hydrogen agencies) twice daily + 75 mg/daily daily +75 mg/ every every 21- day cycle (n=254) sleeper sleeper (n=54)) (n = n=256) Row 4: daily daily (n=22) weekly weekly (n=42) inhibitor inhibitor AZD6244",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading <reliability reliability criteria> (column column 2)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading <reliability reliability criteria> (column column 3)",
      "text": "Row 1: Row Row 2: Row 3: Row Row 4: relevant relevant intervention",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "criteriaExclusion criteriaExclusion criteriaeria;Row Row 2: •week week (n=75) daily daily (n=161) •3) Patients with unstable/Row Row 3: 2015 2015 (102) NCT0066637910 TAILM0] 2012 2012 (cut-off-off January 2013)) Patients with stable/Row Row 3: 2015 2015 (102) NC006379 10 (102 2) NC) N. N.",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: reason",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: NCT00637910 Row 2: TAILOR Row 3:",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (column column 1)",
      "text": "2 mg/m2 TAILOR=daily daily (n=61) • Patients with unstable/Row Row 3: 2015 2015 (102) NCT0067910 TAILor·2012 2012 (cut-off January 2013) ■75 75 mg/ 35 35 mg_m2",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (column column 1)",
      "text": "Row 1: •2015 2015 (107) •International study (Argentina, Argentina, •_MEDTERM0_3 mg/weeks weeks •1) prior prior • 1) Patients aged ≥ non non •Row Row 2: •NCT01673867",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "heading heading <reliability reliability criteria> (column column 2)",
      "text": "Row 1: Row Row 2: Row 3: Row Row 4: Row 5: Excluded",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Spain, Spain, Switzerland) 2013. 2013..Tiren=292) Docetaxel 75 mg/weeks weeks (n=290) ham-based construction, Singapore; Spain, SWitzerland) 2013. 2013. 3) to to relapse/recurrence of •1) Patients aged ≥ clinically clinically and/NSCLC_and NSCLC_and __MIDTERM6___0",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: reason",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: Row Row 2:",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: NCT01708993 Row 2: Row Row 3: Row Row 4:",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (column column 1)",
      "text": "Row Row 2: Spain, Spain, Switzerland) 2013 2013 (n=292) Docetaxel 75 mg/weeks weeks (n=290) more more 3) to to relapse/recurrence of...1) Patients aged ≥ clinically clinically and/NSCLC_and NSCLC_and ECOG PS_0",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "heading heading <reliability reliability criteria> (column column 2)",
      "text": "Row 1: Row Row 2: Row Row 3: relevant relevant mutation",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row Row 2: •75 75 mg/4. 4.5×days days (n=39) mg mg /4, 4,5×4. 4.5× Day Day (n =39) 75 75 mg",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: reason",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: NCT00556322 Row 2: TITAN Row 3: Phase 3",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (column column 1)",
      "text": "1 1 , 21 21 mg/4. 4.5×I I , 75 75 mg/ day day one; days days & 5 5 × 1 1 .days days (n=39) mg mg /day day one",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading <reliability reliability criteria> (column column 3)",
      "text": "Row 1: Row Row 2: Row 3: relevant relevant mutation",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "of of patients",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: reason",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: NCT01798485 Row 2: GALAXY-2 Row 3: Phase 3",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: (111) Row 2: GALAXY-1 Row 3: Phase 2",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: NCT02008227 Row 2: OAK Row 3: Phase 3",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "2 2 (1) of Regulation (EC) No 659/TTP TTP 2°: __medTERM14__, __medTERM14__, ~study study (and and Australia) 2012 2012 (15, 15, 2012) •orally orally + orally orally (n=526) Placebo + orally orally (N=522) ] (1) created created 1",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: reason",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: Row Row 2: (113) Row 3: NCT00440414 Row 4: HORG Row 5: Phase 3",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: NCT01244191 Row 2: MARQUEE Row 3: Row Row 4:",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: OAM4971g (METLung) Row 2: NCT01456325",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (column column 1)",
      "text": "Row 1: Row Row 2: excluded. excluded.",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (column column 1)",
      "text": "regime regime (older older patients) were were examined) aged aged < expected expected (1) Patients aged <___ARMM10___MEDM10______. ___ARMM10___MEDM10______................................ Row 3: 2017 2017 (115) OAM4971g (_MEDTERM7__Lung) NCT01456325• 2013 2013 (cut-offOnartuzumab 15 mg/cycle cycle +",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading <reliability reliability criteria> (column column 2)",
      "text": "Row 1: Row Row 2: Row 3: Row 4: Row Row 5: Row Row 6: relevant relevant assistance",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "criteriaExclusion criteriaExclusion criteriaeria;Row Row 2: 26, 26, 2013).",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: reason",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: 2017 2017 (116) Row 2: NCT01186861 Row 3: Row Row 4:",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (column column 1)",
      "text": "Row 1: Row Row 2: Phase 3°2013. 2013...mg mg (n=250) Placebo IV + orally orally (n=49) (2) disease. disease.",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (column column 1)",
      "text": "Row 1: 2017 2017 (116) NCT01186861 Phase 2",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "heading heading <reliability reliability criteria> (column column 3)",
      "text": "Row 1: Row Row 2: submission Row 3: reason",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "heading heading <reliability reliability criteria> (column column 4)",
      "text": "Row 1: Danish Row 2: and Row 3:",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "(n = n-c) NCT-NCurrent) (NC01362296 Phase 2_MEDTERM0_en) (n=n=N-CowSighter) (now) arm arm (n)years years (range) [ 95% CI]R*Male, n (%).p p (%)n n (%)",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: exclusion",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: Row Row 2: al 2015 (101) Row 3: NCT01362296 Row 4: Phase 2",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: (103) Row 2: NCT01229150; Row 3: CTEP: 8444 Row 4: Phase 2",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: (104) Row 2: NCT01395758 Row 3: Phase 2",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "(NCT01933932) SEL: NCRawH2Right) RowShway 1: arm arm (n))years years (range) [ 95% CI]=Male, n (%).p p (%)-N-clle N-clle c/P-n n % •KRAS £G12C: 18 (40) ] ] Row 4: 2017 2017 (72) NCTC0193533932 marked: pemetrexed pemetrexed (n=45) [58 /71) ]Former: 40 (89)KRASmG12 C: 18.40) ] Row 4: 2017, 2017, (72): NCTT01939339332.32",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: exclusion",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: (72) Row 2: NCT01933932 Row 3: SELECT-1 Row 4: Phase 3",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: (102) Row 2: NCT00637910 Row 3: TAILOR Row 4:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: names names •Thandling arm (n) •years years (range) [ 95% CI] •Male, n (%) •n n 1% •Histology, n % •n n (*) • na na (%) ■Row Row 2: •a a Sc·N-clle N-clle c",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "heading heading <criteria criteria (KRAS G12C KRAS G12C mutation)> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: exclusion",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "heading heading <reliability reliability criteria> (column column 4)",
      "text": "Row 1: years years (range) [ 95% CI] Row 2:",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "heading heading <reliability reliability criteria> (column column 6)",
      "text": "Row 1: Histology, n (%) • n n % Row 2: N-clle N-clle c",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "heading heading <reliability reliability criteria> (column column 9)",
      "text": "Row 1: Row Row 2: sotorasib. sotorasib.",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "of of 2; Prior Prior \"Countover\"Key Inclusion Criteria·Secondary Secondary Endpoints/OligitivesRow 2:",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Sotorasib Row 2: 14",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: > 2 (including anti-Row 2: PD-[L]1 therapies)",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Histologically Row 2: Row Row 3: Row Row 4: Row Row 5: the KRASG12C mutation; Row 6: 0 0 - 2; Row 7: Row Row 8: v1. v1.1; for Row 9: Row Row 10: previous platinum- Row 11: Row Row 12: Row Row 13: therapies, or both",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Active (untreated) Row 2: brain metastases; Row 3: Row Row 4: Row Row 5: Row Row 6: of sotorasib therapy; Row 7: Row Row 8: Row Row 9: Row Row 10: Row Row 11: Row Row 12: Row Row 13: months",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Sotorasib Row 2: 13",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Sotorasib Row 2: 40",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: ≥ 2: 31 (77.5) Row 2: ≥ 3: 19 (47.5)",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: International",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Sotorasib Row 2: 59",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: International",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Sotorasib Row 2: 126",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Anti-PD-(L)1: 91.3% Row 2: Platinum-based CHT",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Level:Rowway:Right right;Right:Rough-Run-T1:R2+Rightway:Showy Name: Study-Dates. Study-Dates.Intervention/Oakables.Row 2: •Row Row 3: •lot lot (Range), • Row 4: _NSCLC in Total",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT03600883 Row 2: Row Row 3: Phase 2",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Sotorasib Row 2: 126",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: USA",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT03785249 Row 2: CRYSTAL-1 Row 3: Phase 1/2",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Adagasib Row 2: 79",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: an an anti-PD-Row 2: (L)1",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: EudraCT: 2005-Row 2: 005393-73 Row 3: Row 4: Phase 2",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Erlotinib Row 2:34",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: advanced NSCLC",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: lesion; __MEDTERM0_0 - 2; Row 4: Row Row 5: Row Row 6: advanced NSCLC",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation> (column column 1)",
      "text": "AgainT2 AgainT2 Right: StudyNow StudyNow 2: Row Row 3: •Median Median (Range), •Row 4: __NSCLC in Total#n n (%) Row 5: strengthenand anti-PD-(L) 1:9: 91.3% and and anti-PPD-Í (L)): 81.0%;2 2 /Data-†Soorrasib 126·Anti-PD‐R-( L) 1: 91.3%) anti anti -PD-$-L): 81.0%)NCT 03600883) 81.",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Exclusive Row 2: riteria Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10:",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "Row 1: n Row 2:",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "Row 1: \"Secondary Secondary Endpoints/Objectives\" Row 2: \"Row 3: \" Row 4: \"NR\" Row 5: \"Row 6: \"following following erlotinibtherapy·FDG FDG &amp; • Row 7: \"Row Row 8: \"prediction of non",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Commission Regulation (EU) even even 1: Inclusion Inclusion Criteria·Secondary Secondary Endpoints/Obligities Row 2: Row Row 3: •chargeLoTmedien chargeLoTmedien (Range), --- Row 4: __NSCLC______REMEDTERM0__ in Total]n n (%) Row 5: NCT02774278 International=NCT0277478 Phase 2",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT02774278 Row 2: International",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT02774278 Row 2: Row 3: Phase 2",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: 2009",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: disease; other Row 3: Row Row 4: last 5 years; brain Row 5: metastases; prior Row 6: anti-Row anti-Row 7: EGFRtherapy",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: Row Row 2: Row Row 3: Row Row 4: clinical benefit (including Row 5: KRASm) Row 6: Secondary: __MEDTERM0_, CBR",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: USA",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NR Row 2: Row 3: Phase 1/2",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Rilotumumab Row 2: Row Row 3: 45",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Row Row 4: __MIDTERM1__",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: Row Row 2: effectiveness (Row Row 3: 70%) Row 4: Secondary: OS, PFS",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: China",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT00816868 Row 2: C-TONG0807 Row 3: Phase 2",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Enrollme Row 2: nt: Feb Row 3: Row Row 4: Sept Row 5: 2009",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: capcitabine Row 3: 58",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: treatment",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: 12-week Row 2: Row Row 3: Secondary: Row Row 4: __MIDTERM2___. __MIDTERM2___.",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation> (column column 1)",
      "text": "Row 1: Author Country...Author Row 2: • Country Row 3: NCT0277427 International • NCCT0277427 Row 4: • International Row 5: USA USA • Row Row 6: • USA Row 7: Zhao, 201 China",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Commission Regulation (EC) right right holder: Study. Study.DatesIntervention/Row Row 2: CERow CERow 3: •Patients with \"LoT\" (Range), • 'Range', 'Row 4: ~n n (%) 0 5: 2 2 /June June 2009^responsibilityAdvanced responsibilityAdvanced ___MEDTM9___; •Unstable system disease; 5 5 years; brain mettasses; previous metise; previous actions;",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: 78 Row 2: l",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: 17 Row 2:",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: 15 Row 2:",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Commission Regulation (58) Canada/IND.196 Phase: 9 (59) ]Media 2 (29) /and and __MEDTERM9_Drimary: 2 CHT: 31 (100) Radiation: 18 (55) Other: 9 (229) (1) and and ................n n (%) Row 5: Jan Jan 2013",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Canada",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Phase 1",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: 2013",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: RP2D Row 2: Secondary: descriptive Row 3: Row Row 4: and and PD",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: USA",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT01302808 Row 2: Row 3: Phase 1",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: 2014a",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: erlotinibRow 3: 17",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: safety, Row 2: Row Row 3: Secondary: Row Row 4: PK",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: USA",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Antroquinoneol Row 2: 30",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: histologically Row 3: confirmed non-",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "cancer cancer prevention;2 2 (anti-dumping anti-dumping law; More than 5: Phase Phase 2•Dec Dec 2018[set set up: set set set: 31 ]Antrohoh wol/n (%) Row 5: nCT02077344 International",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT02047344 Row 2: International",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT02047344 Row 2: Row 3: Phase 2",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: 2018",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: (stage IV); disease Row 3: Row Row 4: Prior LoTs (Row Row 5: platinum-based) or Row 6: Row Row 7: Row Row 8: approved treatments; Row 9: Row Row 10: Row Row 11: RECIST v1.1; Row Row 12: Row Row 13: available; __MIDTERM1_0 - 2",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: USA",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT02417701 Row 2: Row 3: Phase 2",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Row Row 4: 2020a",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: TAK228 Row 2: 21",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: ORR Secondary: Row 2: PFS",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: United States",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NR Row 2: Row 3: Phase 2",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Enrollme Row 2: nt: Sept Row 3: Row Row 4: Jun 2016",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Defactinib Row 2:55",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Leptomeningeal Row 2: metastasis",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: 12-week PFSRow 2: rate Row 3: Secondary: __MIDTERM0__, OS, ~MEDTERM3__, Row 4: and safety",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation> (column column 1)",
      "text": "Row 1: Author Country...Author Row 2: • Country Row 3: NCT0204734 Internationa.. . . ..Row Row 4: \"Internationa Row 5: USA. USA...\"Row Row 6: \"USA Row 7: A. A.\"",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "to to right;Key Inclusion Criteria:Secondary Secondary Endpoints/Obligives Row 2: Row Row 3: Dec Dec 2018;set set set: 30 Safety set: 31 •cancer cancer analysis; 2018, 2018, Set: 30 Security set: 32",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: 44 Row 2: al",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: 20 Row 2:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row+Row+T2: 1:Jun 2014_MEDM0_ 20ah- 2hH1:Row=to to 1: 0RowGo right: Study. Study.DatesIntervention/Oakies Row 2: •Row Row 3: •Criteria Criteria (Range), • Row 4: n n (%) - Row 5: Row Row 6: \"Row 6: 'FAK inhibitor; __MEDERTM14____Row 7: ~1. 1. ■ Row 8: Phase Phase 1: 'Enrollme nt: Jun Jun 2014",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Nokihara, Row 2: 2019 Row 3: Japan",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT0153656 Row 2: Row 3: Phase 1",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Enrollme Row 2: nt: 28 Row 3: March Row 4: Row Row 5: Jun 2014",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Cabozantinib Row 2: 20",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: ≥ 3: 20 (100) Row 2: CHT: 20 (100), Row 3: BEV: 10 (50) Row 4: Nivolumab: 1 (5) Row 5: TKI: 19 (95) Row 6: Crizotinibs: 1 (5), Row 7: ~MEDTERM2__S: 10/50) Row 8: }MEDTERM3___Y: 13 (65) Row 9: •MEDTERM4___: 1 (20)",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: MTD and/or Row 2: Row Row 3: Row Row 4: Row Row 5: Row Row 6: Row Row 7: received ≥ Row Row 8: cabozantinib.",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation> (column column 1)",
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: \" Row 4: Nokihara, 2019 Japan\" Nokihara, Row 5: \"2019 Row 6: \"Japan\"",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row Row 2: • Row Row 3: • Study Row 4: • Row 5: • 1 1 • NLT0155365 Row 6: ■ Row 7: ▪ phase 1",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "Row 1: tudy Row 2: Row Row 3:y",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "Row 1: \"Dates\" Interface Row 2: \"Row Row 3: \"Row Row 4: \"Row Row 5: \"Row 6: 56\" \"Enrollme nt: Jun Jun 2014·_MEDTERM0___20__MEDTERM0_\" Row 7: \"20 Row 8: \"",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation> (column column 4)",
      "text": "Row+H H , Wow Wow 3: ithowow-T Median (Range), ororRow 4: n n (%) • Row 5: CERow 6: ceFAK inhibitor; Nivolumab_____5 (5) TKI: 19 (95) __ENTTERM1___: 1 (5) ___MEDERTM1__: 5 (5) __medTERM2___: 10 (50) __midTERM3____ 20 (100) CHT: 20 (100] BEV: 10 (565) ___MIDTERM4___ 1: 1 (5) TCI: 1995 ___",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation> (column column 5)",
      "text": "Row 1: Row Row 2: Crit Row 3: Row 4: Row 5: R Row 6:",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation> (column column 6)",
      "text": "Row 1: xclusion Row 2: teria Row 3: Row 4: Row 5: Row 6:",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation> (column column 7)",
      "text": "Row 1: \"Secondary Secondary Endpoints/Objects Row 2: \" Row 3: \"Primary: MTD and/received received ≥ __MEDTERM0_. __MEDTERM0_.",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row+RightH1:right right right- right right right= Secondary Secondary Endpoints/Oaks Row 2: Row Row 3: •Media Media (Range), --- Row 4: n n (%) # Row 5: 2. 2.6) 2: 6 (31.6)2: 13 (68.4) KRASav12C 1: 6 (38.4) May May 2019·May May 2019; ___MEDTERMM0__in Total",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT02642042 Row 2: USA",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT02642042 Row 2: Row 3: Phase 2",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Row Row 4: 2019",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: Row Row 2: Secondary: Row Row 3: Row Row 4: KRAsm Non-G12C; grade Row 5: 3 - 5 AE",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: USA",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT01192165 Row 2: Row 3: Phase 1b",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Oct Row 4: 2013a",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Row Row 4: (Row Row 5: colony- Row 6: stimulating Row 7: factor [G-CSF]) Row 8: Row Row 9: Row Row 10:95",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary (Part 1): RP2D Row 2: Primary (expansion Row 3:cohort): ORR",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation> (column column 1)",
      "text": "Row 1: Author Country...Author Row 2: ..Country Row 3: NCT0264204 USA.. . . ..NCT026504 Row 4: ..USA Row 5: USA. USA. ..Row Row 6: A. A.",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "5 (68.4) KRASm Non-G12C1 (28.6) 2: 25 (71.4):16 (29.6) 2: 38 (70.5) KRASG12C 1: 6 (31.6) 2: 13 (68.4) 12C 12C 1:10 (28.6.6) 2:25 (771.4), 16 (29.6)):16 (229.6). 2:38 (69.6) G12C G12C 1:13 (28.5) 2:25 (71.14.4) +2 (79.6):16 (9.29.6)2:29.6 2:38 (770.4) RRASG 12C 1:6 2: 13 (31.6) KRACSm Nnon-G11C 1: 10 (28.6) C 1:10 (\"2.4) 2:21.4) 4:16 (27.6) 3:16 (39.6) 2.38 (70.7.4) n n (%):9.4) DRASG2:26.) KREAS_QTURRP 1: SeaRSSS+United United AG; WE: 7R even USRA: right:iR",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1:42 Row 2:",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: 17 Row 2:",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "of of Justice; right right right: \"Row Row 3: \"lies lies (Range), --- Row 4: _NSCLC_ in Total·n n (%) 0 5: •or uncontrolled •Row 3: •Patents over •systemic diseases • Row 7: Phase Phase 1b£Conduct eded: more. more.KRASASm; metastatic=Question Question (21 days_toward_ into",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: USA",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT02258607 Row 2: NR Row 3: Phase 1b",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Conduct Row 2: ed: Row 3: March Row 4: Row Row 5: March Row 6: 2017",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Momelotinib Row 2: Row Row 3: 21",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: Row Row 2: Row Row 3: cycle Row 4: Secondary: Row Row 5: 8; ORR; PFS, __MIDTERM2__",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Huijberts, Row 2: 2020 Row 3: Netherlands",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT02230553 Row 2: Row 3: Phase 1",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: 2019a",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: trametinib Row 3: 15",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: RP2R Row 2: Secondary: Row Row 3: Row Row 4: Row Row 5: and PK",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation> (column column 1)",
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: \" Row 4: Barbie, 201 USA\" \"Row Row 5: \"USA Row 6: Huijberts, 2020\" \"Huijberts,\" Row 7: \"2020 Row 8: \"Netherlands\"",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: \"Row Row 2: \"Row Row 3: \"Study Row 4: \" Row 5: \" 18 \" 1b 1b \" Nct022586\" Row 6: \"NR Row 7: \"Row Row 8: \"NCT0223055 Phase 1\" NCT0223055 Row 9: \"Row 10\": \"Phase 1\"",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "Row 1: tudy Row 2: Row Row 3:y",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "Row 1: \"Dates\" Dates Row 2: \"Row 3: \"07\" Conduct ed: 2017 2017 \"Conduct Row 4: \"Added: Row 5: \"March Row 6: \"Row Row 7: \"March Row 8: \"2017 Row 9: \"De De 2019a· Row Row 10: \"Row Row 11: \"2019a",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "Row 1: 53 Row 2: Row 3:",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation> (column column 4)",
      "text": "The right-over-Right of DRT-tas-path path inhibitors;Aright-way_right-a- right-way-way=Right-way -right, right, right-on-right, right: secondary secondary Endpoints/Oobjectives Row 2: \"Row Row 3: \"Median Median (Range), 'Row 4: n n (%) --- Row 5: •Row Row 6: ^systemagy (21 days) Row 7: to to study; inhibitors inhibitors (21 day) systems systems (28 days) or immuno",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation> (column column 4)",
      "text": "Row 1: 14 Row 2: ec Row 3:",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "right right USA: Inclusion Inclusion Criteria·Secondary Secondary Endpoints/Oliteives Row 2: \"Row Row 3: \"Patients within 'LoT Middle (Range), ' Row 4: _NSCLC_ in Total#n n (%) # 5:",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: 5 countries: Row 3: Row Row 4: and Europe.",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT01155453 Row 2: Row 3: Phase 1b",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Enrollme Row 2: nt: May Row 3: Row Row 4: Jan 2013",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: __MEDTERM0_17",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: 3 (1 - 14)",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: Row Row 2: Row Row 3: Secondary: safety, PK; Row 4: Row Row 5: predictive/PD biomarkers",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <Local adaptation> (column column 1)",
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: \" Row 4: \"Europe. Europe.\"\"Row Row 5: \"Row Row 6: \"Row Row 7: \"and Europe.\"",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "right right right- right right right: Secondary Secondary Endpoints/Oobjectives Row 2: \"Row Row 3: \"a a 'LoT Media' (Range), ' Row 4: ___medTERM2__in Total#n n (%) Row 5: •occlusion; previous",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Commission Regulation (right right right: secondary secondary Endpoints/Oliteives Row 2: \"Number of sleep' Row 3: \"time time Time' (Range), 'Row 4: ____NSCLC in Total·n n (%) #5: Bardia, 2020 International",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: International",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT01363232 Row 2: Row 3: Phase 1b",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Row Row 4: 2014 Row 5: (data Row 6: cutoff)",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: tumors; disease Row 3: Row Row 4: Row Row 5: and/Row Row 6: Row Row 7: available; evaluable Row 8: Row Row 9: v1.1; 2. 2.",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: Row Row 2: Secondary: Row Row 3: PD",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Switzerland",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT02964689 Row 2: Row 3: Phase 1b",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Enrollme Row 2: nt: May Row 3: Row Row 4: Dec 2019",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Binimetinib, Row 2: Row Row 3: cisplatin Row 4: 18",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Australia & Row 3: New Zealand",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NR Row 2: Row 3: Phase 1",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Conduct Row 2: ed: 20 Row 3: Row Row 4: Row Row 5: 2017",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Lifirafenib Row 2: 19 (Row Row 3: escalation + 10 Row 4: dose expansion)",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: All cancers: ≥ 3 (inc. Row 2: Row Row 3: treatment) 50% Row 4: prior surgery ≥ 75%",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: escalation: Row Row 3: Row Row 4: Row Row 5: Secondary: Row Row 6: of of SD",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Commission Regulation (EU) right right right- Secondary Secondary Endpoints/OakiesRow 2: \"Row Row 3: \"journey journey Criteria', 'Range), ' Row 4: _NSCLC in Total#n n (%) 0 5: •mutation-grade mutation-grade ≥ prior prior ] Row 3: 'Patents of slowly'Row 6: tumors tumors ~ Row Row 7: Pase Pase 1;Enrolle nt nt: Apr Apr 2018__MEDTERTERM0_/PD-03-0325901 to 11",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Netherlands",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT02039336 Row 2: Row 3: Phase 1",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Enrollme Row 2: nt: Apr Row 3: Row Row 4: Apr 2018",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Dacomitinib_/PD-Row 2: 0325901 Row 3: 11",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: At least 2: Row 2: antineoplastic Row 3: Row Row 4: disease",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: Row Row 2: schedule Row 3: Secondary: Row Row 4: Row Row 5: activity, PK",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Germany",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NR Row 2: Row 3: Phase 1",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Enrollme Row 2: nt: Oct Row 3: Row Row 4: Dec 2013",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: sorafenibRow 3: 16",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: Row Row 2: Secondary: Row Row 3: Row Row 4: response",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT00098254, Row 2: 2021 Row 3: USA",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT00098254 Row 2: Row 3: Phase 2",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: 2011",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: (Sorafenib_) Row 3:37",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation> (column column 1)",
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: \" Row 4: Netherlands. Netherlands...\"van Geel,\" 202 Row 5: \"Netherlands Row 6: Nogova, 202 Germany\" \"Row Row 7: \"Germany Row 8: NCT0009825 2021 \"USA\" NCT009825 Row 9: \"2021 Row 10: \"USA",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: \"Row Row 2: \"Row Row 3: \"Study Row 4: \" Row 5: \" 20 \" 1 1 \" Nct020392 Row 6: \" Row 7: \" Row Row 8: \" 1 1 'NR Row 9: \" Bow 10 \": \"Row Row 11: \" 2 2 \" NTT000982 Row 12: \"Row 13: \" Phase 2",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: 20 Row 2:",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: 54, Row 2: Row 3:",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "Row 1: tudy Row 2: Row Row 3:y",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "Secondary Secondary Endpoints/Oobjectives) Row 2: Number of 5: cup 5: \"grade grade ≥ Row Row 6: • Row Row 7: 36;Enrollme nt: Apr Apr 2018Dacomitinib___/PD-0325901 11 ]At least 2: advancedd advancedd disease; At least 2: anteoplast 2: advanced advanced disease;Histologically or",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "Row 1: 54 Row 2: Row 3:",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "NIRNRowRight+rightHonder1 rightHonder1 1: Secondary Secondary Endpoints/ObligeicesRow 2: \"Row Row 3: \"Middle Middle (Range), # Row 4: n n (%) Register Row 5: •Row Row 6: \"with KRASm^ Row 7: in in Total#p p (%) 0 5: n n % Ro Ro 5: Row 6: 'WIT WIT 6: 3 (1 - 10) ];NR",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: NR",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT01021748 Row 2: NR Row 3: Phase 1",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: selumetinibRow 3: 19",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Lopez-Chavez, Row 2: 2015 Row 3: USA",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT01306045 Row 2: CUSTOM Row 3: Phase 2",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Selumetinib Row 2: monotherapy Row 3: Row Row 4: Row Row 5: mutationb Row 6:481",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Histologically Row 2: Row Row 3: Row Row 4: (Row Row 5: neuroendocrine Row 6: tumors), Row Row 7: malignancies",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Huijberts, Row 2: 2020 Row 3: Netherlands",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT2450656 Row 2: Row 3: Phase 1",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: RP2R Row 2: Secondary: anti-tumor Row 3: and and PD",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation> (column column 1)",
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: \" Row 4: NR NR 'Tolcher', 201 Row 5: \"NR Row 6: \"Lopez-Chave 2015 \" USA \" Lopez -Chave Row 7: \" 2015 Row 8: \"USA Row 9: \"Huijberts, 2020\" Netherlands \"Huijberts,\" Row 10: \"2020 Row 11: \"Netherlands\"",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "RowRow+Case Case (Range) -Ex Ex Crit=Row Row 2: \"Row Row 5: 'Row 6: 15°Phase Phase 1: 'All All cancers: 3 (1 - 10) n n (%) 0 0 5: 0 0 ]5 5 7: Row Row 8:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: ez, Row 2: Row 3:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "Row 1: xclusion Row 2: teria Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation> (column column 4)",
      "text": "Row 1: •Secondary Secondary Endpoints/Objects • Row 2: • response response • Raw 3: • With KRASm· Row 4: • Dose finding: MTD in",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "right right Run: right right right: Secondary Secondary Endpoints/Oliteives.Row 2: \"Row Row 3: \"Middle Middle (Range), # Row 4: _NSCLC in Total",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: ClinicalTr Row 2: ils.gov",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: sites",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NR Row 2: Row 3: Phase 1",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: 1: 2 (8) Row 2: 2: 12 (50) Row 3: ≥ 3: 10 (42)",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: NSCLC with KRASm; Row 4: ECOG PS ≤ 1; life Row 5: expectancy ≥ 12 Row 6: weeks; Measurable Row 7: Row Row 8: v1.1; ≤ Row Row 9: __MIDTERM0__",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Row Row 4: Row Row 5: Row Row 6: Row Row 7: ocular disorders",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: and antitumour activity",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT02031458 Row 2: BIRCH Row 3: Phase 2",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Atezolizumab Row 2: 667",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Cohort 1: none Row 2: Cohorts 2: 1 Row 3: Cohorth 3: ≥ 2",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Row Row 4: NSCLC; Row Row 5: expression; Row Row 6: or 1; Measurable",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: pneumonitis, Row 4: autoimmune Row 5: Row Row 6: viral diseases; Prior Row 7: treatment with",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Commission Regulation (EU) 2RS2 2RS2 Run:of of StudySubDatesInterventionInventions/Oobjectives Row 2: •Row Row 3: \"1. 1. .1. 1.).or or ICIRange), --- Ro 4: __medTERM5__in Total",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: v1.1.",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: ICIs",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Atezolizumab Row 2: 204",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: May Row 4: 2016",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Atezolizumab Row 2: Row Row 3: 28",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: __MEDTERM0_0 or 1; Row 2: Row Row 3: 1. 1.",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: Row Row 2: tolerability Row 3: Secondary: Row Row 4: response; DoR, __MIDTERM1__, OS",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Unclear",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT02779751 Row 2: Row 3: Phase 1b",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: pembrolizumab Row 3: 50",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Cohort A: CHT-naïve Row 2: Cohorts B: 68% Row Row 3: line of CHT",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: with ≥ 1% Row Row 3: non-Row non-Row 4: squamous __MEDTERM0_Row 5: Row Row 6: subtype; ≤ Row Row 7: platinum-containing Row 8: CHT regimenn",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: Row Row 2: Row Row 3: Row Row 4: Secondary: Row Row 5: DoR, __MIDTERM2__, ~MEDTERM3__, PK",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation> (column column 1)",
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: \" Row 4: \"Eberhardt, Row 5: \"2017 Row 6: \"Unclear Row 7: \"Hellmann, 2019 International\"Hellman, Row 8: \"2019 Row 9: \"International Row 10: Pujol,\" 202 Unclear \"Row Row 11: \"unclear\"",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Commission Regulation (EC) 1T2Sa 1T2Sa right= ShownH1Right+Rowpjump1RowRunHo Hoer 1: Criteria Criteria Criteria·Criteria Criteria (\"Key Review Criteria')Key Key 4: ___medTERM5___in Total#n n (%) Row 5: •number of justice: 1;1. 1.",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: 20 Row 2:",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Commission Regulation (EU) No 561 II: 32 -B5: 3Paclitma: 76 (41) Cable: 76, 76: 76-Pace of Study_Supp_T2: Rowt+T2Rightway; RowsRowt=1B 1B (85) PemeLIN Phase 1b) initiation initiation : n n (%) 5: phase phase 1b/initiation initiation :184, 184, / n n (%) # (%) Row 5: 1 1 b",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: USA",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT01772004 Row 2: JAVELIN Row 3: Phase 1b",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Enrollme Row 2: Row Row 3: treatmen Row 4: t Row 5: initiation Row 6: : Row Row 7: Row Row 8: Row Row 9: 2014",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary:Row Row 2: Row Row 3: Row Row 4: Secondary: Row Row 5: Row Row 6: PD-Row PD-Row 7: Row Row 8: IC",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: USA",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Nivolumab Row 2: 129",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: ≥ 3 prior therapies: Row 2: 54%",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: USA",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Enrollme Row 2: nt: Jul Row 3: Row Row 4: March Row 5: 2018",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: ipilimumab Row 3: 9",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: IB - IIIA treatment-Row 3: Row Row 4: confirmed NSCLC; Row 5: __MIDTERM1__0 • 1ALK",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: Row Row 2: Row Row 3: Row Row 4: Row Row 5: secondary secondary endpoint",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation> (column column 1)",
      "text": "Row 1: Author Country...Author Row 2: ..Country Row 3: USA. USA.. ..Row Row 4: ..USA Row 5: Rizvi Rizvi , 201 Row 6: •USA Row 7: USA. USA. . . ..Row Row 8: ■USA",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row Row 2:",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: 17 Row 2:",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: 14 Row 2:",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: 20 Row 2:",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "Row 1: tudy Row 2: Row Row 3:y",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "7Rightway ¡of of Justice: \"n n (%) account Row 5: •initiation initiation : p p (%) n n (%) rain 5: 'treatmentitiation treatmentitiation : _ _ 25) Gemminage: 32 (17) ___MEDTERMM2____: 20 (11) Doce exports:18 (10) Vinorelbine: 9 (5) (5) Cabboline: 77 100 (54) Pacli nt: 76 (41) 76 76 (44) Cesplatin: 46 (25 (2525) C Ces: 46 (27) (25 (25) 2_ 2_ 6_: 18; DoD: 18 (10) Office: 18 (9) (10) W): 18 (10) Commission: 18-10:I (10): Iran (10): 9 (10): Commission: Commission Commission: 9: Ho: Union: 9!: Commission C: Commission Council: 9 (5), C: 9 5: Commission CarIn: Commission -: Commission.: Commission rent: Commission",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation> (column column 3)",
      "text": "Row 1:04 Row 2: Row 3:",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation> (column column 4)",
      "text": "Row 1: \"Secondary Secondary Endpoints/Objects Row 2: \"Primary:treatment treatment Secondary: __MEDTERM1_, __MEDTERM1_, ~Row Row 3: \"NR Row 4: un",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Commission Regulation (EUR even lotsRight) 1 2R2RSa right=Right+Inclusion Inclusion Criteria·Secondary Secondary Endpoints/Row Row 2: •Row Row 3: lung lung ~Row 7: \"dise; ................ Row 8: \"preoperative CHT; n n (%) Row 5:",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Unclear",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT01124864 Row 2: NR Row 3: Phase 2",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Conduct Row 2: ed: Oct Row 3: Row Row 4: Nov 2014",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: AUY922 Row 2: 153",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: cytologically Row 3: Row Row 4: NSCLC; ≥ Row Row 5: Row Row 6: Row Row 7: cohort (_MEDTERM0___ < 2).",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "5 (41.8) + 0 0 9: •Targeted yesterday (41.2) 0 (41) 9 9 9: \"Row 6 10: \"KRASwt 1 (2.9) • Row 11 (32.4) • KREASm 7: ^KRASm 6 (21.4) ] •KRASm 6 (6.21.4) --- Row 8:",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Study",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Secondary Row 3: Endpoints/Objects",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: USA",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row 3: Phase 2",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: 2019a",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Bortezomib Row 2: 16",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Uncontrolled Row 2: Row Row 3: involved the CNS; at Row 4: Row Row 5: peripheral Row 6: neuropathy; Row 7: Row Row 8: boron or mannitol",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Primary: Row Row 2: Secondary: Row Row 3: toxicity",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: Malhotra, Row 2: 2018 Row 3: USA",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation>",
      "text": "Row 1: NCT01649947, Row 2: NCT00728845 Row 3: Row 4: Phase 1b",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation> (column column 1)",
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: \" Row 4: \"USA USA \"Row Row 5: \"USA Row 6: USA USA \"Malhotra,\" Row 7: \"2018 Row 8: \"US",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "right right right- Secondary Secondary Endpoints/Oligitives Row 2: \"Row Row 3: \"Patients with 'LoT Media' (Range), 'Row 4: ___medTERM0___in Total#n n (%) Row 5: 'Targeted therapy': 'Row 6 (32.4) •KRASwt 1 (2.9) ] ] Row 7 7: ^KRasm 6 (21.4) --- Row 8 8: lies 8: .All 64 (41.8)",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation> (column column 2)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading <Local adaptation:>",
      "text": "into into account:Right-right-right, right, Right-arrow-rightright-way-ways of-waywayway-way way-waysway-through-way.Row 3: • Row 4: PopulationPopulation/NSCLC_ NSCLC_ (NSCLCRow NSCLCRow 5: night-time) __medTERM0__mutation __medTERM0__mutation or",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "heading heading <Local adaptation:>",
      "text": "Row 1: Row Row 2: Row Row 3: • Row Row 4: • Row Row 5: • Row Row 6: Row Row 7: Row Row 8: terms. terms.",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "heading heading < local local adaptation>",
      "text": "Row 1: Publication type...and and .. Row 2: •systematic systematic reviews*.. ..Row 3: • Row 4: • Country • Not restricted • Raw 5: Other criteria • Other criteriaia•population population (size) and • Bow 6: reporting (baseline characteristics) Row Row 7: ■ Row 8:",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading < local local adaptation>",
      "text": "Commission Regulation (EU) 2015-A-PD-Storasib-Ansti-P (L)): 91.",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading < local local adaptation>",
      "text": "Row 1: Author Row 2: Country",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading < local local adaptation>",
      "text": "Row 1: Row Row 2: Study Row 3: Name, Row 4: Row Row 5: Study",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading < local local adaptation>",
      "text": "Row 1: Date Row 2: s",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading < local local adaptation>",
      "text": "Row 1: Prior Row 2: Therapy Row 3: Row 4: Row Row 5: (Range), Row 6: Row Row 7: (%)",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading < local local adaptation>",
      "text": "Row 1: Row Row 2: Criteria",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading < local local adaptation>",
      "text": "Row 1: Key Row 2: Exclusion Row 3: Criteria",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading < local local adaptation>",
      "text": "Row 1: Row Row 2: Row Row 3: Endpoints/Obj Row 4: ectives",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading < local local adaptation>",
      "text": "Row 1: Skoulidis Row 2: ,2021",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading < local local adaptation>",
      "text": "Row 1: NCT03600 Row 2: 883 Row 3: CodeBrea Row 4: Row Row 5: Phase 2",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading < local local adaptation>",
      "text": "Row 1: Data-Row 2: cutof Row 3: Row Row 4: 15, Row 5: Marc Row 6: h Row 7: 2021.",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading < local local adaptation>",
      "text": "Row 1: Anti-PD-Row 2: (L)1: 91.3% Row 3: Platinum-Row 4: Row Row 5: and anti-PDF-ROW 6: (L): 81.0%",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading < local local adaptation>",
      "text": "Row 1: Primary: Row 2: safety, Row 3: Row Row 4: Row Row 5: DLT Row 6: Secondary: PK, Row 7: Row Row 8: Row Row 9: of SD",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading < local local adaptation> (from previous page)",
      "text": "Row 1: ...right right right- tumor tumor 3) January January 1) for for ≥ to to screening). (1) Mixed •1°: Row Row 11:",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading < local local adaptation> (from previous page)",
      "text": "Row 1: Platinum-Row 2: based Row 3: combination Row 4: therapy, Row 5: targeted Row 6: Row Row 7: both",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading < local local adaptation> (from previous page)",
      "text": "Row 1: Janne, Row 2: 2017",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading < local local adaptation> (from previous page)",
      "text": "Row 1: NCT019339 Row 2: 32, Row 3: SELECT-1, Row 4: Internatio Row 5: nal study",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading < local local adaptation> (from previous page)",
      "text": "Row 1: cond Row 2:ucted Row 3: betw Row 4: one Row 5: Octo Row 6: ber Row 7: 2013 Row 8: and Row 9: Janua Row 10: ry Row 11: 2016",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading < local local adaptation> (from previous page)",
      "text": "Row 1: Row Row 2: selumetin Row 3: ib Row 4: (hydroge Row 5: n Row 6: sulphate) Row 7: twice Row 8: daily + 75 Row 9: mg/Row Row 10: docetaxel Row 11: intraveno Row 12: Row Row 13: Row Row 14: every 21- Row 15: Row Row 16: (n=254) Row 17: Row 18: Matched Row 19: placebo Row 20: plus Row 21: docexole Row 22: (same Row 23: schedule) Row 24: (N=256)",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading < local local adaptation> (from previous page)",
      "text": "Row 1: 1) Row Row 2: Row Row 3: Row Row 4: histologically Row 5: or Row 6: cytologically Row 7: confirmed Row 8: locally Row 9: Row Row 10: metastatic Row 11: NSCLC (stage Row 12: IIIB^IV). Row 13: 2) Patients Row 14: Row Row 15: Row Row 16: Row Row 17: Row Row 18: advanced Row 19: Row Row 20: centrally Row 21: confirm Row 22: KRAS-mutant Row 23: tumor Row 24: 3) Row Row 25: performance Row 26: Row Row 27: 1",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading < local local adaptation> (from previous page)",
      "text": "Row 1: 1°: PFS Row 2: 2°: Row Row 3: Row Row 4: Row Row 5: tolerability,",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading < local local adaptation> (column column 1)",
      "text": "three, three, #2",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading < local local adaptation> (column column 2)",
      "text": "Row 1: Row 2: Anne, Row 3: 2017 Row 4:",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading < local local adaptation> (column column 3)",
      "text": "Row 1: • Row 2: • studio studio • NCT01 Row 3: • 32, Row 4: • SELEF Row 5: • Intern Row 6: ■nal stu",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading < local local adaptation> (column column 4)",
      "text": "Row 1: • Row 2: 19339 • 201 201 •con Row 3: •uct Row 4: CT-1, •bet Row 5: •een Row 6: outy •Oct Row 7: ■ber Row 8: ▪201 Row 9: ●and Row 10:",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading < local local adaptation> (column column 5)",
      "text": "Row 1: ..tumor tumor 3) 1 1 January1) for for ≥ to to screening). (1) Mixed:1°: PF 2° n (and and anti",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading < local local adaptation> (column column 6)",
      "text": "Row 1: Row 2: FS Row 3: Row Row 4: , TTP, Row 5: Row Row 6: rability,",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading <Unpublished data> (from previous page)",
      "text": "Row 1: Trial name: CodeBreak 100°NCT number: NCT03600883",
      "start_page": 157,
      "end_page": 157
    },
    {
      "heading": "heading heading <Unpublished data> (column column 3)",
      "text": "Row 1:00°NCT number: NCT0360088",
      "start_page": 157,
      "end_page": 157
    },
    {
      "heading": "heading heading <Unpublished data> (from previous page)",
      "text": "Row 1: Trial name: CodeBreak 100°NCT number: NCT03600883",
      "start_page": 158,
      "end_page": 158
    },
    {
      "heading": "heading heading <Unpublished data> (column column 4)",
      "text": "Row 1:00°NCT number: NCT03600883",
      "start_page": 158,
      "end_page": 158
    },
    {
      "heading": "Table 40: SELECT-1 • Study Characteristics",
      "text": "Row 1: Trial name: CodeBreak 100°NCT number: NCT03600883",
      "start_page": 159,
      "end_page": 159
    },
    {
      "heading": "Table 40: SELECT-1 • Study Characteristics",
      "text": "Row 1: Trial name: SELECT-1°NCT number: NCT01933932",
      "start_page": 159,
      "end_page": 159
    },
    {
      "heading": "heading heading <Main exclusion:>",
      "text": "Row 1: Trial name: SELECT-1°NCT number: NCT01933932",
      "start_page": 160,
      "end_page": 160
    },
    {
      "heading": "heading heading <Main exclusion:> (column 5)",
      "text": "Row 1: NCT number: NCT01933932",
      "start_page": 160,
      "end_page": 160
    },
    {
      "heading": "heading heading <Exploratory Outcome variables:>",
      "text": "Row 1: Trial name: SELECT-1°NCT number: NCT01933932",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "heading heading <Exploratory Outcome variables:> (column 2)",
      "text": "Row 1: NCT number: NCT019339",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "heading heading <Exploratory Outcome Variables:> (from previous page)",
      "text": "Row 1: Trial name: SELECT-1°NCT number: NCT01933932",
      "start_page": 162,
      "end_page": 162
    },
    {
      "heading": "heading heading <Exploratory Outcome variables:> (column column 6)",
      "text": "Row 1: NCT number: NCT01933932",
      "start_page": 162,
      "end_page": 162
    },
    {
      "heading": "heading heading <information information None>",
      "text": "Row 1: Trial name: SELECT-1°NCT number: NCT01933932",
      "start_page": 163,
      "end_page": 163
    },
    {
      "heading": "heading heading <information information None>",
      "text": "Row 1: Inclusion Criteria... Sotorasib.. ..Docetaxel Row 2: •(CodeBreak 100) • (SELECT-1)",
      "start_page": 163,
      "end_page": 163
    },
    {
      "heading": "heading heading <outcome outcome measures>",
      "text": "right right right!N= 256 Row 2: Age (mean) Row Row 3: Gender (% feale) Gender (feale) + 50% Row 4: Brain metastases (%) +21%.NRb Row 5: ECOG (% PS 1 [vs PS 0]) •70%·59% Row 6: Race (% white) ^82%c # 95% Row 7: % KRAS-G12Cl100%#42% Row 8: Anti-PD-(L) line line lines)",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "heading heading <outcome outcome measures>",
      "text": "Row 1: Outcome meansDefinition:Validity:Clinical relevance",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "heading heading <outcome outcome measures> (column 1)",
      "text": "Row 1: Baseline characteristics (CodeBreak 100) N = 126 Row 2: Age (mean) Row Row 3: Gender (% female) •50% Row 4: Brain metastases (%) •21% Row 5: ECOG (% PS 1 [vs PS 0]) −70% Row 6: Race (% white) ~82%c Row 7: % KRAS-G12C·100% Row 8: Anti-PD-(L) prior prior line(s) ^91% Row 9: lines lines (% with 1/2/3 prior lines) ■43%/35%/22% Row 10: baseline baseline (% IIIB[vs IV]) ‐97% Row 11: Histology (% Non-square)",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "heading heading <outcome outcome measures> (column 1)",
      "text": "Row 1: Outcome meansDefinition:Validity:Clinical relevan",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "heading heading <outcome outcome measures> (from previous page)",
      "text": "Row 1: Outcome meansDefinition:Validity:Clinical relevance",
      "start_page": 165,
      "end_page": 165
    },
    {
      "heading": "heading heading <outcome outcome measures> (column column 4)",
      "text": "Row 1: \"Definition·Validity\"",
      "start_page": 165,
      "end_page": 165
    },
    {
      "heading": "heading heading <outcome outcome measures> (column column 5)",
      "text": "Row 1: Clinical Relevance",
      "start_page": 165,
      "end_page": 165
    },
    {
      "heading": "heading heading <Results per study>",
      "text": "Row 1: Outcome meansDefinition:Validity:Clinical relevance",
      "start_page": 166,
      "end_page": 166
    },
    {
      "heading": "heading heading <Results per study> (column 1)",
      "text": "Row 1: Outcome meansDefinition:Validity:Clinical relevan",
      "start_page": 166,
      "end_page": 166
    },
    {
      "heading": "heading heading <X>",
      "text": "Row 1: XX • Row 2: • X Row 3: ■ Row 4: ~ X ~ Row 5: ~X ~ Raw 6: ▪ X ^ X Row 7: · Row Row 8:",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "heading heading <X> (column 1)",
      "text": "Row 1: XX • Row 2: ■ Row 3: ▪ Row 4: • X Row 5: · X Row 6: ~ X Row 7: ^ X Row 8: ● X Row 9: ♫ X",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "heading heading <X> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7:",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "heading heading <X> (column 6)",
      "text": "Row 1: • Row 2: ■ Row 3: ▪ Row 4: ~ Row 5: − Row 6: ● Row 7: ·",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "heading heading <X> (column 7)",
      "text": "Row 1: X Row 2: Row 3: X Row 4: X Row 5: X Row 6: X row 7: X",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "heading heading <X> (from previous page)",
      "text": "Row 1: X Row 2: X°X Row 3: X°x Row 4: X° X Row 5: X° x Row 6: • Row 7: X*X Row 8: X· Row 9: X~X Row 10: X^X Row 11: X/*X Row 12: X=X Row 13: X",
      "start_page": 168,
      "end_page": 168
    },
    {
      "heading": "heading heading <X> (column column 1)",
      "text": "Row 1: Row 2: X Row 3: X Row 4: X Row 5: X Row 6: Row 7: X Ruw 8: X Raw 9: X Bow 10: X Rock 11: X Roll 12: X Row 13: X-Row 14: X - Row 15: X, Row 16: X",
      "start_page": 168,
      "end_page": 168
    },
    {
      "heading": "heading heading <X> (column column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15:",
      "start_page": 168,
      "end_page": 168
    },
    {
      "heading": "heading heading <X> (column column 7)",
      "text": "Row Row 15:",
      "start_page": 168,
      "end_page": 168
    },
    {
      "heading": "heading heading <X> (column column 9)",
      "text": "Row 1: X Row 2: X Row 3: X Row 4: X Row 5: X Row 6: Row 7: X Ruw 8: X Raw 9: X Bow 10: X Row 11: X Rock 12: X Roll 13: X-Row 14: X - Row 15: X",
      "start_page": 168,
      "end_page": 168
    },
    {
      "heading": "heading heading <Page 166/237> (from previous page)",
      "text": "Row 1: adverse adverse events: Sotorasib (CodeBreak-100)*·Docetaxel + placebo (SELECT-1)** Row 2:",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading <Page 166/237> (column column 1)",
      "text": "Row 1: Row Row 2:",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading <Page 166/237> (column column 2)",
      "text": "Row 1: Row Row 2:",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading <Page 166/237> (column column 3)",
      "text": "Row 1: asib (C Row 2: n",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading <Page 166/237> (column column 4)",
      "text": "Row 1: CodeBreak-100)* Row 2: n=126",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading <Page 166/237> (column column 5)",
      "text": "two. two...",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading <Page 166/237> (column column 6)",
      "text": "Row 1: Docetaxel + pl Row 2:",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading <Page 166/237> (column column 7)",
      "text": "Row 1: placebo Row 2: n=254",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading <Page 166/237> (column column 8)",
      "text": "Row 1: o (SELECT-1) Row 2: 4",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading <Page 166/237> (column column 9)",
      "text": "Row 1: )** Row 2:",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "adverse adverse events",
      "text": "Row 1: event. event...Sotorasib (CodeBreak-100)*·Docetaxel + placebo (SELECT-1)** Row 2:",
      "start_page": 176,
      "end_page": 176
    },
    {
      "heading": "adverse adverse events",
      "text": "Row 1: event. event...Sotorasib (CodeBreak-100)*·Docetax Row 2: \"n=126\" (%)• Row 3: \"Row 3:\"\"",
      "start_page": 176,
      "end_page": 176
    },
    {
      "heading": "adverse adverse events",
      "text": "Row 1: xel + placebo (SELECT-1)** Row 2: n=254 (%)",
      "start_page": 176,
      "end_page": 176
    },
    {
      "heading": "heading heading <adverse adverse events> (from previous page)",
      "text": "17, 17, (2, 9 9), 9 9 9: Arthralaa ) (21.4);3.4 (24.4) and (2.9) Row 7 (22.8) 7 7 (31.0) ow 7 7: 39 39 (99.2);77 (61.1))235 (92.2)) ceRow 4: Anew gradeGrade 3++.8)2 2 + Row 5: Any AE/125 (99.2)) 177 (61.21.1)235 (92.5)) •115 (45) (45) Row 6: Diarrhoea64 (5.8),7 (50.8) •7 (54.4) ^7 (55.4)",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 1)",
      "text": "Row 1: Row Row 2:",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 2)",
      "text": "Row 1: Advert Row 2:",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 3)",
      "text": "Row 1: Row Row 2:",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 4)",
      "text": "Row 1: Ents Row 2:",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 5)",
      "text": "Row 1: Sotorasib (C Row 2: n=",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 6)",
      "text": "Row 1: CodeBreak-100)* Row 2: =126 (%)",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 7)",
      "text": "Row 1: Row 2:",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 8)",
      "text": "Row 1: Docetaxel + p Row 2: n=",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 9)",
      "text": "Row 1: placebo Row 2:=254 (%",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 10)",
      "text": "Row 1: o (SELECT-1) Row 2: %)",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 11)",
      "text": "Row 1: )** Row 2:",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading <adverse adverse events> (from previous page)",
      "text": "Row 1: Rash •8 (6.3) •0 (0) •28 (11.0) •1 (0.4) Row 2: Headache •11 (8.7) • 0 (0) ■26 (10.2) •NA Row 3: Myalger • 8 (6.3)",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 1)",
      "text": "Row 1: Rash •8 (6.3) •0 (0) Row 2: Headache •11 (8.7) • 0 (0) Row 3: Myalga • 8 (6.3) *0 (0)",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "heading heading <adverse adverse events> (column column 2)",
      "text": "Row 1: 1 (0.4) Row 2: NA Row 3: NA",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "heading heading <X *population population (N =126)>",
      "text": "Row 1: XX°-Row 2: X°-X°-x°-Row 3:",
      "start_page": 182,
      "end_page": 182
    },
    {
      "heading": "heading heading <X *population population (N =126)>",
      "text": "Row 1, NA-events events & SELECT-1 45%) Comparon ((61%- 45%)) /45%) Row 12: 100 100 -5.8% (8.7%-NA 40% NA-na-na",
      "start_page": 182,
      "end_page": 182
    },
    {
      "heading": "heading heading <Page 178/237>",
      "text": "X-X-l-X: X-SX-X - X-Row* X-JX- ð X-HX-II-X+X-I-XX-TX-WX-x-X^X-OX-VX-AX-MX-ZX-UX-LX-FX-CX-NX-PX-QX-GX-BX-, X-",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading <Page 178/237>",
      "text": "Row 1: X",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading <Page 178/237>",
      "text": "Row 1:",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading <Page 178/237>",
      "text": "Row 1:",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading <Page 178/237>",
      "text": "Row 1:",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading <Page 178/237>",
      "text": "Row 1:",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading <Page 178/237> (column 1)",
      "text": "Row 1: X· X* X* ■ X* Row 2: ^ X*",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading <Page 178/237> (column 1)",
      "text": "Row 1: X· X* X * X * ~ X * Row 2: X^ X * x * X ~ * Row 3: X■ X * * X = X *",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading <Page 178/237> (column 1)",
      "text": "Row 1: X· X* X * X * * X \" Row 2: X ■ X * x * X ~ X *",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading <Page 178/237> (column 1)",
      "text": "Row 1: • x • X • * X ■ X X ~ X Row 2: X \\ X ^ X − X __ ~ ~ Row 3: X } ~ x ~x ~X ~",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading <Page 178/237> (column 1)",
      "text": "Row 1: X· X* X* x* X * X* Row 2: X*X* X > X*",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading <Page 178/237> (column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading <X X>",
      "text": "Court Court Court",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "heading heading <XX> (column 1)",
      "text": "Row 1: • X",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "heading heading <X X> (column 5)",
      "text": "Row 1: X",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "heading heading <X X> (column 10)",
      "text": "Row 1: X°X",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "heading heading <X X>",
      "text": "Court Court Court",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "heading heading <XX> (column 1)",
      "text": "Row 1: • X",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "heading heading <X X> (column 5)",
      "text": "Row 1: X",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "heading heading <X X> (column 10)",
      "text": "Row 1: X°X",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "heading heading <Side 181/237>",
      "text": "Row 1: X",
      "start_page": 187,
      "end_page": 187
    },
    {
      "heading": "heading heading <Side 181/237> (column 5)",
      "text": "Row 1: X·X^X-X-Row 2: X*X-~X-Row 3: X· X-~x-X - Row 4: X■ X- * X- ~ X-°-X ~- X ~ ~ - ~",
      "start_page": 187,
      "end_page": 187
    },
    {
      "heading": "heading heading <data data sources>",
      "text": "Row 1: Study characteristics: Sotorasib (CodeBreak 100) (87)·docetaxel docetaxel (SELECT-1) (72) Row 2: Blinding•Row Row 3: Inclusion criteria: patients patients (> 18 years) Status Status 0",
      "start_page": 188,
      "end_page": 188
    },
    {
      "heading": "heading heading <investigators investigators in>",
      "text": "Row_Right_S$-T2; M_M2_BAR_RIGHT; Row 1: Row; R right; Rright; ROW 1 Row: Row, Rowh_Row-1 1 •Received Received >regime regime (is is acceptable) Row 3: investigation-assesed investigation-assesed __FORMEDMM1___MEDARM1_",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "heading heading <investigators investigators in>",
      "text": "Row 1: Baseline characteristics a· Sotorasib (CodeBreak 100) n=126(87) ■docetaxel docetaxel (SELECT-1) (n=256) (130) Row 2: Age",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "heading heading <indirect indirect comparisons>",
      "text": "holder holder (% female) four four 3% Row 2: Brain metastases (%) of21%#NRc Row 3: Performance status (ECOG or WHO; % PS 1 [vs PS 0]) •70%=59% Row 4: Race (% white) 82%d^95% Row 5: % KRAS G12C_-muted",
      "start_page": 190,
      "end_page": 190
    },
    {
      "heading": "heading heading <X X X>",
      "text": "Row 1: X",
      "start_page": 192,
      "end_page": 192
    },
    {
      "heading": "heading heading <SET SET 2>",
      "text": "Row 1: N N = 256°N N = 98°sotorasib sotorasib N= 98 Row 2: CovariatesSELECT-1·CodeBreaK 100•Row Row 3: ECOG (% PS 1 [vs PS 0])",
      "start_page": 193,
      "end_page": 193
    },
    {
      "heading": "heading heading <SET SET 2> (column 1)",
      "text": "Row 1: N N = 256 Row 2: CovariatesSELECT-1 Row 3: ECOG (% PS 1 [vs PS 0]) •x Row 4: Age (mean) ■x Row 5: baseline baseline (%) • x Row 6: Smoking status (% ever smoker) \\x Row 7: level level (<5% vs ≥ 5%) ~x Row 8: Gender (% female) }x Row 9: Histology (% Non-squamous) ^x",
      "start_page": 193,
      "end_page": 193
    },
    {
      "heading": "heading heading <Overall Overall survival>",
      "text": "Row 1: Race (% white)",
      "start_page": 194,
      "end_page": 194
    },
    {
      "heading": "heading heading <Overall Overall survival>",
      "text": "19. 19.",
      "start_page": 194,
      "end_page": 194
    },
    {
      "heading": "heading heading <Progression-free Progression-free survival>",
      "text": "16normal 16normal Gamma:326.7",
      "start_page": 197,
      "end_page": 197
    },
    {
      "heading": "heading heading <score score analysis>",
      "text": "21.73% cohortRow cohortRow 2: •n=% copyrightRow copyrightRow 3: Row Row 4: ~N = 206) ^N = 120.57) • Row 5: Platinum-based chemotherapy",
      "start_page": 201,
      "end_page": 201
    },
    {
      "heading": "to to Forecasts",
      "text": "(N) baseline baseline (Y; N) expression expression (<1%, 1-49%, expression expression (< 1%, 1- 19%, 1-19%, < 100%), No PD-P-base base (Y); N) expression expression = 1%, (1) - 1-9%,< 50%), No P-L1, 50%). the the Commission'107 107 (3) (c) Union Union (\"TFEU') 108 108 (3) TFEU. TFEU.",
      "start_page": 204,
      "end_page": 204
    },
    {
      "heading": "heading heading < X X X>",
      "text": "Row 1: XX",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "heading heading < X X X>",
      "text": "Row 1: XX • Row 2: X • X Row 3: ■ X ~ Row 4: • x ~ X ^ X Row 5: X − X \\ X } X Row 6: X",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "heading heading <X>",
      "text": "X-X-S-X-2X-X-4X-Row-XX-O-X-1 X-x-X-3 X-Z-X-5 X-J-X-7 X-N-X-8 X-Q-X-0 X-ax-X-9 X-M-X-6 X-",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "heading heading <X>",
      "text": "Row 1: X· Row 2: X· X ■ X ~ Row 3: X * X X ^ X • Row 4: X \\ Row Row 5: X",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "heading heading <X>",
      "text": "Row 1: XX°-Row 2: X°-X-X Row 3:",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "heading heading <X>",
      "text": "X-X-ax-X: X-x-row-XX-X ðX-Row-ZX-SX-JX-TX-WX-MX-HX-OX-YX-KX-UX-QX-AX-CX-GX-FX-PX-VX-BX-, X-*X-+X-",
      "start_page": 208,
      "end_page": 208
    },
    {
      "heading": "heading heading <X X>",
      "text": "Row 1: X° X° x° X' Row 2: X° Row 3: X°X° X 'X' Row 4: X* X' X' # X's Row 5: X°x' X \"X Row 6: X· X'X' X 'Row 7: X^",
      "start_page": 209,
      "end_page": 209
    },
    {
      "heading": "heading heading <XX> (column 1)",
      "text": "Row 1: X°X",
      "start_page": 209,
      "end_page": 209
    },
    {
      "heading": "heading heading <XX> (column 1)",
      "text": "Row 1: X-X Row 2: X-x Row 3: X-ax Row 4: X-Z-X",
      "start_page": 209,
      "end_page": 209
    },
    {
      "heading": "heading heading <Missing values>",
      "text": "Row+right right (0.8) Row 5: ALT (U/L) n (%); #12 (5.3) .1 (0.8) Row 6: Albumin (g/L), n (%) 071 (l/min/1.73m2) n (%)85 (37.8) •1 (0.8) Row 4: ALT [U/ L) ~ n (%) 12 (U) •11 (5.9) 1 (0.0) Row 7: Albumin (g / L) ] n (%)7 (kg/m2) •7 (3.1) •3 (2.4) Row 9: Smoking history",
      "start_page": 215,
      "end_page": 215
    },
    {
      "heading": "heading heading <Missing values> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: d Row 19: e Row 20: Row 21:",
      "start_page": 215,
      "end_page": 215
    },
    {
      "heading": "heading heading <for for __",
      "text": "Row 1: •Control • Sotorasib Row 2: KRAS mutant • Row 3: Unadjusted • 206 • 119 Row 4: Adjusted (ATT) • 104.8 •119 Row 5: G12C~ Row 6: Unadjusted • 85·119 Row 7: Adjusted (ATT) ■ 17.8 •119 Row 8: Key: treated treated •",
      "start_page": 219,
      "end_page": 219
    },
    {
      "heading": "heading heading <mutation. mutation.",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8:",
      "start_page": 219,
      "end_page": 219
    },
    {
      "heading": "heading heading <ECOG: 1 74.27% 70.59% 70.46%>",
      "text": "Row 1: Baseline characteristics:Row Row 2:",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "heading heading <ECOG: 1 74.27% 70.59% 70.46%> (from previous page)",
      "text": "Row 1: 240.028% Row 3: Prior PD-(L)1 immunotherapy: Yes·73.30% •90.76% •90.64% Row 4: Prior Platinum-based chemotherapy: Ye*84.47% •89.39% Row 5: Albumin (g/L) 00 00 •Row Row 6: Key: AST, aspartate transaminase; mass mass index; filtration filtration rate; protein protein 1; 1 1 Note: variables variables (albumin)",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "heading heading <ECOG: 1 74.27% 70.59% 70.46%> (from previous page)",
      "text": "21.75% Rows: 74 74 years•35.29%·57% Row 6: Presence of __MEDTERM0_/_MEDTERM1_/BRAF/ROS-1 mutation8.24%",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "heading heading <ECOG: 1 74.27% 70.59% 70.46%> (column column 1)",
      "text": "Row 1: 24.40.29% Row 2: 3·23.30% Row 3: Prior PD-(L)1 immunotherapy: Yes•73.30% Row 4: Prior Platinum-based chemotherapy: Yes*84.47% Row 5: Albumin (g/L) *37.26",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "heading heading <ECOG: 1 74.27% 70.59% 70.46%> (column column 1)",
      "text": "Row 1: Row Row 2: •Control Row 3: ECOG: 1.70.59% Row 4: Brain metastasis: Yes·30.59% Raw 5: Metastatic: Yes^90.59% Row 6: Presence of EGFR/ALK/BRAF/ROS-1 mutation8.24%",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "heading heading <ECOG: 1 74.27% 70.59% 70.46%> (column column 1)",
      "text": "Row 1: 41. 41.18% Row 2: 35. 35.29% Row 3: ≥ 23. 23.53% Row 4: BMI (kg/m2) 26.25",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "heading heading <ECOG: 1 74.27% 70.59% 70.46%> (column column 1)",
      "text": "Row 1: 1°34.12% Row 2: 2°40.00% Row 3: 3°25.88% Row 4: Liver metastasis: Yes·11.4.12% Row 5: Prior PD-(L)1 immunotherapy: Yes^65.88% Raw 6: Prior platinum-based chemotherapy: Ye*87.06% Row 7: Albumin (g/L) 37.57",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "heading heading <(N = 85) (N = 133.11)>",
      "text": "21.73% cohortRow cohortRow 2: •n=% copyrightRow copyrightRow 3: Row Row 4: ~N = 206) ^N = 120.57) • Row 5: Platinum-based chemotherapy",
      "start_page": 226,
      "end_page": 226
    },
    {
      "heading": "heading heading <(N = 85) (N = 133.11)> (column 1)",
      "text": "Row 1: Regimen... Unweighted coder.. .. Row 2: \"n\" % of coder.\"",
      "start_page": 226,
      "end_page": 226
    },
    {
      "heading": "heading heading <(N = 85) (N = 133.11)> (column 1)",
      "text": "Row 1: •(N = 206) • Row 2: Platinum-based chemotherapy • 64.07% • Row Row 3: Chemotheragy monotherapy (excludes the clerks) ■61 • 29.61% • Row Row 4: ramucirumab_45 ramucirumab_45 • 21.84% • Row Row 5: Docetekler monotherapy •21°10.19% • Row Row 6: regimenns regimenns • 15·7.28% • Row Row 7: ▪",
      "start_page": 226,
      "end_page": 226
    },
    {
      "heading": "heading heading <(N = 85) (N = 133.11)> (column 1)",
      "text": "Row 1: •(N = 85) • Row 2: Platinum-based chemotherapy • 25.41% • Row Row 3: Chemotheragy monotherapy (excludes the attendants) − 24.24% • Row Row 4: Docetaxel plus __MEDTERM0_·18°21.18% • Row Row 5: Docetables monotherapy ■ 11.94% ~ Row Row 6: Other chemotherapy-based regimenns",
      "start_page": 226,
      "end_page": 226
    },
    {
      "heading": "heading heading <Overall Overall survival>",
      "text": "Row 1: X Row 2: X",
      "start_page": 227,
      "end_page": 227
    },
    {
      "heading": "heading heading <Overall Overall survival>",
      "text": "Row 1: X°-Row 2: ...X°-x°-row 3: . . . X°, X° X° - Row 4: X°/X°, Row 5: X°X° and Row 6: X′ X°",
      "start_page": 227,
      "end_page": 227
    },
    {
      "heading": "heading heading <X>",
      "text": "4 4 (1) of Regulation (EU) No 182/the the Commission'powers powers (p. p. 13).",
      "start_page": 228,
      "end_page": 228
    },
    {
      "heading": "heading heading <X>",
      "text": "Row 1: X Row 2: X",
      "start_page": 228,
      "end_page": 228
    },
    {
      "heading": "heading heading <X>",
      "text": "Row 1: X Row 2: X",
      "start_page": 228,
      "end_page": 228
    },
    {
      "heading": "heading heading <X> (column 1)",
      "text": "Row 1: Model/Unrestricted Row 2:",
      "start_page": 228,
      "end_page": 228
    },
    {
      "heading": "heading heading <Progression-free Progression-free survival>",
      "text": "4 4 (1) of Regulation (EU) No 182/2011.",
      "start_page": 230,
      "end_page": 230
    },
    {
      "heading": "heading heading <Progression-free Progression-free survival> (column 1)",
      "text": "Row 1: Distribution·Independent fit \"sotorasib\" Independent fit - chemo-Joint fit (unrestricted)",
      "start_page": 230,
      "end_page": 230
    },
    {
      "heading": "heading heading <X>",
      "text": "Row 1: X Row 2: X",
      "start_page": 231,
      "end_page": 231
    },
    {
      "heading": "heading heading <X>",
      "text": "Row 1: X Row 2: X",
      "start_page": 231,
      "end_page": 231
    },
    {
      "heading": "Table 69. EQ-time time points",
      "text": "21,2+right right stock!Orighthose1 -2nd 2nd 2: Row 2: REUN=124) Row 3: Row 3: • Row 4: ~% Row Row 5: ceNumber;number;numbber;0 0 6: Assessment Time scoreCcompleted·Expected*set#% Row Row 7: Baseline",
      "start_page": 243,
      "end_page": 243
    }
  ]
}